BMJ Open

Creation of an electronic patient-reported outcome measure platform Voxe: A protocol in pediatric solid organ transplantation

Journal:	*BMJ Open*
Manuscript ID	bmjopen-2021-053119
Article Type:	Protocol
Date Submitted by the Author:	05-May-2021
Complete List of Authors:	Anthony, Samantha; The Hospital for Sick Children, Child Health Evaluative Sciences; University of Toronto, Factor-Inwentash Faculty of Social Work Pol, Sarah; The Hospital for Sick Children, Child Health Evaluative Sciences Lin, Jia; The Hospital for Sick Children, Child Health Evaluative Sciences Barwick, Melanie; The Hospital for Sick Children, Child Health Evaluative Sciences; University of Toronto, Dalla Lana School of Public Health Brudno, Michael; University Health Network, Data Aggregation, Translation and Architecture; University of Toronto, Faculty of Arts and Science Manase, Dorin; University Health Network, Data Aggregation, Translation and Architecture Parekh, Rulan; The Hospital for Sick Children, Child Health Evaluative Sciences; The Hospital for Sick Children, Transplant and Regenerative Medicine Centre Silva, Amanda; University Health Network, Data Aggregation, Translation and Architecture Stinson, Jennifer; The Hospital for Sick Children, Child Health Evaluative Sciences; University of Toronto, Lawrence S. Bloomberg Faculty of Nursing
Keywords:	Quality in health care < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Transplant medicine < INTERNAL MEDICINE, MENTAL HEALTH, PAEDIATRICS, Paediatric transplant surgery < PAEDIATRIC SURGERY, QUALITATIVE RESEARCH

SCHOLARONE™
Manuscripts

BMJ

I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our licence.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which Creative Commons licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Title

Creation of an electronic patient-reported outcome measure platform Voxe: A protocol in pediatric solid organ transplantation

Authors

Samantha J. Anthony[1-4], Sarah J. Pol[1], Jia Lin[1], Melanie Barwick[1,5,6], Michael Brudno[7,8], Dorin Manase[7], Rulan S. Parekh[1,2,9,10], Amanda Silva[7], Jennifer Stinson[1,11]

1. Child Health Evaluative Sciences, Peter Gilgan Centre for Research and Learning, The Hospital for Sick Children, Toronto, ON, Canada
2. Transplant and Regenerative Medicine Centre, The Hospital for Sick Children, Toronto, ON, Canada
3. Factor-Inwentash Faculty of Social Work, University of Toronto, Toronto, ON, Canada
4. Canadian Donation and Transplantation Research Program, Edmonton, AB, Canada
5. Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada
6. Temerty Faculty of Medicine, Department of Psychiatry, University of Toronto, Toronto, ON, Canada
7. Data Aggregation, Translation and Architecture, University Health Network, Toronto, ON, Canada
8. Faculty of Arts and Science, Department of Computer Science, University of Toronto, Toronto, ON, Canada
9. Division of Nephrology, The Hospital for Sick Children, Toronto, ON, Canada
10. Division of Nephrology, University Health Network, Toronto, ON, Canada
11. Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, ON, Canada

Author	ORCID
Samantha J. Anthony	0000-0002-1800-2333
Sarah J. Pol	0000-0003-1883-1753
Jia Lin	0000-0002-8691-3358
Melanie Barwick	0000-0002-2478-604X
Michael Brudno	0000-0001-7947-2243
Rulan S. Parekh	0000-0001-6313-5752
Jennifer Stinson	0000-0002-9969-8052

Corresponding author

Samantha J. Anthony

The Hospital for Sick Children

686 Bay Street, Toronto, Ontario, M5G 0A4

E-mail: samantha.anthony@sickkids.ca

Word count: 3255

Abstract

Introduction:

Patient-reported outcome measures (PROMs) provide an opportunity for meaningful patient engagement and shared decision-making. The objective of this research program is to improve health outcomes for pediatric solid organ transplant patients by implementing PROMs into clinical care. The current study aims to create Voxe, a pediatric user-centred electronic PROM platform, by engaging pediatric patients and healthcare providers throughout the design and development process.

Methods and analysis:

The creation of Voxe will occur over two phases that build on previous research. The user interface design phase will employ a 'user-centric' approach to identify end-users' needs and iteratively refine the look and layout of Voxe to meet these needs. Transplant recipients and healthcare providers will participate in three rounds of testing. During virtual sessions, participants will: (1) complete task-based activities (outcomes – effectiveness and efficiency), (2) complete questionnaires (outcome – satisfaction), and (3) participate in a semi-structured interview. The following phase will involve software development and Voxe usability testing. Transplant recipients and healthcare providers will participate in four rounds of iterative testing. The think-aloud technique will be employed, and participants will describe their thoughts and feelings while interacting with a Voxe prototype to complete structured tasks. Participants will: (1) log into Voxe and complete tasks (outcomes – participant compliance, time on task, successful task completion, frequency of critical and non-critical errors and error-free

rate), and (2) participate in a semi-structured interview. Findings will result in the creation and launch of a user-centred electronic PROM platform prototype.

Ethics and dissemination:

Research ethics board approval has been provided by The Hospital for Sick Children. This research is critical to answering methodological and operational questions that will inform Voxe implementation in pediatric clinical settings and facilitate PROM data collection. Future investigations will include an implementation-effectiveness evaluation of the Voxe platform.

Article Summary – Strengths and limitations of this study

- By engaging pediatric patients and healthcare providers throughout the design and development process, this study will facilitate the creation and launch of an evidence-based pediatric user-centred electronic PROM platform prototype called Voxe

- A 'user-centric' approach will consider the needs of pediatric patients and healthcare providers at each design phase and allow for iterative modification of wireframes to best meet their identified needs.

- The think-aloud technique will facilitate understanding of the end-user's experience with Voxe by enabling participants to verbalize their thoughts and feelings while interacting with Voxe to complete specific tasks.

- As the ability to speak and read English is a requirement for study participation, the perspectives of those who are not able to speak and read English will be missed in these phases of the study.

- This study builds the foundation for future phases of research which will include
  healthcare provider Voxe orientation and competency training and an implementation-
  effectiveness evaluation.

Keywords

- Quality in health care

- Transplant medicine

- Mental health

- Paediatrics

- Paediatric transplant surgery

- Qualitative research

BACKGROUND

For children with end-stage organ failure, transplantation is a life-saving therapy.(1, 2) However, evaluating the success of solid organ transplantation based solely on objective clinical outcomes is insufficient. The patient's subjective assessment is a crucial component in evaluating the burden of disease and can be captured via patient-reported outcome measures (PROMs).(1, 2) PROMs are defined as: "any report of the patient's health condition that comes directly from the patient, without interpretation of the patient's response by a clinician or anyone else" (pg. 2).(3) PROMs can capture a patient's self-assessment of functional status, symptoms, treatment adherence, and multiple domains of well-being and quality of life.(4, 5) In doing so, PROMs give patients a voice in their healthcare and provide an opportunity for meaningful engagement.(6) Research indicates that the systematic collection of PROM data enhances patient-clinician communication and shared decision-making, thereby improving health outcomes.(4, 5, 7, 8) The inclusion of PROMs in clinical care assists in identifying valuable information about the impact of transplantation on patients' symptoms as well as their functional and emotional status. This in turn may help healthcare providers to detect under- and unrecognized problems (e.g., depression, anxiety), resulting in more effective patient care (e.g., initiation of clinical interventions) and an efficient healthcare system.

Innovative opportunities to integrate PROMs into clinical practice have been buoyed by recent advances in eHealth.(9, 10) In particular, the development and implementation of electronic PROMs (ePROMs) can help identify important, patient-valued concerns at the point of care, supporting the delivery of appropriate and timely interventions. Moreover, current platforms that support the use of ePROMs are underdeveloped and require better

implementation with clinical care.(2, 6, 7) Further, research on the implementation

effectiveness of ePROMs in pediatric clinical settings is limited,(2, 11) giving rise to concerns

that ePROMs may languish, unused, and fail to realize meaningful outcomes for patients.

Implementation of evidence-based interventions is important to ensure meaningful patient

outcomes.(12) Achieving optimal clinical and health system outcomes for ePROMS will require

more intentional and explicit study of how they might best be implemented prior to

widespread implementation.(1, 2, 5)

The overarching objective of this research program is to improve health outcomes and

transform the delivery of care for pediatric transplant patients in Canada by integrating

ePROMs into standard clinical practice. This program of research uses a phased approach to

target the methodological and practical decisions (e.g., determining which standardized PROMs

to use, identifying goals for collecting PROMs, selecting patients, setting, and timing of

assessment, etc.) needed to guide systematic and effective implementation of ePROMs into

'real-world' pediatric patient care settings.(13) Recently completed foundational research to

explore these questions within pediatric solid organ transplantation consisted of the three

phases of work outlined below.

Phase 1: Systematic review

A systematic review was conducted to identify PROMs used in pediatric solid organ

transplantation.(14) A total of 4,305 studies were identified, of which 62 describing 47 PROMs

were selected for analysis and were appraised for adherence to internationally recommended

guidelines for item generation, item reduction, and psychometric properties.(15) Findings

revealed six standardized PROMs that had undergone psychometric evaluation in a pediatric

solid organ transplant population. This phase of work identified standardized PROMs to consider for implementation into clinical care.

Phase 2: Interviews with key stakeholders

Interviews with key stakeholders across Canada, including: (a) pediatric solid organ transplant recipients, (b) parent(s)/caregiver(s), and (c) healthcare providers, were conducted to explore perspectives regarding ePROMs implementation into clinical practice.(16) Sixty-three participants across five Canadian pediatric transplant centres were interviewed, among whom nearly all (60/63; 95%) were supportive of implementing an ePROM system into clinical practice with the primary goals of: (1) integrating the transplant patient's overall well-being into the clinical care conversation, (2) capturing the patient's voice and increasing patient engagement, and (3) informing pediatric transplant clinical care. Insights for effective PROM implementation included the remote completion of ePROMs in advance of clinical appointments for patients eight to 10 years of age or older.

Phase 3: Consensus workshop

A two-day consensus workshop was hosted in December 2018 in Toronto to further explore how ePROMs could best be implemented into pediatric transplant clinical practice. Workshop proceedings were informed by the results of Phases 1 and 2. The workshop was attended by 25 leading experts in the fields of pediatric solid organ transplantation, PROMs, implementation science, and computational medicine, as well as patients, caregivers, healthcare providers, researchers, and administrators from across Canada. Workshop outcomes included: (1) consensus on key methodological and operational decisions for implementing ePROMs into practice (e.g. which standardized PROMS to utilize, the setting and timing of

assessment, as well as the mode for administering ePROMs), (2) a research plan to design, develop and evaluate the usability and implementation of an ePROM platform, and (3) a knowledge translation strategy to disseminate research findings to key knowledge users (e.g. newsletter, peer-reviewed publications, website posting, national and international presentations). The consensus workshop captured attendees' perspectives on practice and systems-based facilitators and barriers to implementing ePROMs and was instrumental in ensuring that future research would be relevant and meaningful to stakeholders.

Study objectives

Results from Phases 1 to 3 inform the current study, Phases 4 and 5.(17) The overarching aim of the proposed study, which will be conducted within the Transplant and Regenerative Medicine Centre at The Hospital for Sick Children (SickKids), is to create an ePROM platform called Voxe, that will capture and implement patient-reported outcomes into the clinical care workflow for pediatric organ transplant patients. Specifically, Phase 4 aims to design the user interfaces of the Voxe platform, and Phase 5 aims to develop the Voxe software and conduct usability testing of Voxe in preparation for a future implementation-effectiveness trial (Phase 6). A graphical representation of the different research phases is displayed in Figure 1: *Measuring What Matters: Implementing Patient-Reported Outcome Measures into Clinical Practice – A Research Program*.

METHODS

Phase 4: User interface design of Voxe ePROM platform

eHealth technologies designed and developed based on assumptions of end-user motivations, goals or needs, are often less effective than those that engage end-users throughout the process.(10, 18) Thus, a 'user-centric' approach in which end-users (i.e., patients and healthcare providers) are central to the design process will guide the design and development of Voxe. This evidence-based approach will consider the needs of Voxe users at each design phase and will allow for iterative modification of wireframes to best meet their identified needs.(19) A 'user-centric' approach is paramount for user engagement with the platform, ultimately contributing to the effectiveness of the platform itself.(10)

Study participants and inclusion criteria

Purposive sampling will be used to recruit 12 patient participants across age, organ type, sex, gender, and ethnicity from the Transplant and Regenerative Medicine Centre at SickKids to obtain maximum variation.(20) Twelve members of the patients' interdisciplinary healthcare teams at SickKids will also be recruited purposively across professional disciplines, years of practice, sex, gender and ethnicity. This sample size is consistent with testing methods for clinical information systems.(21)

Patients eligible to participate include those who are: (a) 10 to 17 years of age, (b) able to speak and read English, and (c) heart, kidney, liver or lung transplant recipients who are a minimum of three months post-transplant. Patients with significant cognitive impairments, as determined by a healthcare team member, will not be invited to participate. Eligible healthcare

providers include any member of the interdisciplinary healthcare team within the Transplant and Regenerative Medicine Centre at SickKids.

Procedures and outcomes

The design of preliminary Voxe wireframes will be guided by: (1) stakeholder input gleaned from previous phases of research,(14, 16) and (2) design workshop processes, including identification of Voxe users (i.e., patients and healthcare providers) and the tasks they will complete on their respective platforms (i.e., persona and task inventory development). Following the design of preliminary wireframes, a rapid and iterative testing methodology will be used to evaluate, learn and improve Voxe prior to development (i.e., coding and launch).(19) Three rounds of testing sessions will be scheduled with patient and healthcare provider participants to elicit feedback on Voxe design features. Written consent and assent, as well as demographic information, will be obtained prior to study participation.

Each testing session will be conducted virtually via the Personal Health Information Protection Act-compliant version of Zoom or Microsoft Teams. During each session, International Organization for Standardization key performance indicators, consensus-base standards for technology, will be benchmarked and tracked to validate each iteration for success.(22, 23) In particular, objective and subjective standards common in user experience design testing,(24) will be collected to measure: (1) effectiveness – accuracy and completeness with which users achieve specific goals, displayed as a percentage of tasks successfully completed by users, and (2) efficiency – resources used in relation to results achieved, represented by the time it takes users to successfully complete the task.(25) Prior to the scheduled testing session, the URL for the testing website will be emailed to the participant.

During the session, participants will complete task-based activities using incremental segments (i.e., wireframes) of the Voxe platform.

Following the task-based activities, healthcare provider participants will complete a Likert scale questionnaire to assess the key performance indicator satisfaction. Patient participant's overall impression and experience with the Voxe platform will be evaluated using the Microsoft Desirability Toolkit.(26) Patient participants will select five words from a list of product reaction words to describe their attitude towards the Voxe platform. Product reaction words, such as "fun" and "calm" describe intangible emotional response towards the interface.(27)

Lastly, participants will share their likes and dislikes of the Voxe platform design and comment on the platform's ease of use and elements of functionality during a virtual semi-structured qualitative interview. Semi-structured interviews foster reciprocity between the participant and interviewer, allow the interviewer to ask pertinent follow-up questions to elicit rich data and enable the participant to express themselves using their own words.(28-30) The interview guide will be developed by the study team and will be informed by clinical knowledge and experience. Interviews will be conducted by study team members trained in qualitative methods. Sessions will be audio-recorded, transcribed verbatim and de-identified to protect participant confidentiality. Recruitment for Phase 4 began in May 2020.

Data analysis

Data collected during the testing sessions, including objective and subjective International Organization for Standardization key performance indicators, will be used to refine Voxe. The research team will utilize content and thematic analysis to categorize the data

collected during qualitative interviews.(31-33) Two members of the study team experienced in

qualitative methods, will code the data independently, and categories will be reviewed and

refined until consensus is reached for emerging themes. Trustworthiness will be achieved by

facilitating member checking and soliciting rich description during interviews, as well as hosting

frequent team meetings to support in-depth, iterative analysis with reflexive discussion among

team members. Analysis will be complete once the research team agrees that thematic

saturation is attained.(33) NVivo 12 will be used to manage qualitative data.(34) Quantitative

data collected during the testing sessions will be triangulated with qualitative themes to

provide a richer understanding of end-users' experience with Voxe. Refinements will be made

to the Voxe platform design based on the triangulated data. Three rounds of iterative feedback

testing will be conducted with each participant population (i.e. four participants per round)

until Voxe is considered acceptable to participating end-users with no further refinements

identified.(35, 36) Following the third round of patient and healthcare provider iterative testing,

the design team will share the final Voxe patient and healthcare provider annotated wireframes

with the development team.

Phase 5: Development of ePROM platform Voxe and usability testing

Usability is defined as the "extent to which a system, product or service can be used by

specified users to achieve specified goals with effectiveness, efficiency and satisfaction in a

specified context of use".(22) To test Voxe usability, the think-aloud technique will be

employed in which participants will verbalize their thoughts and feelings while interacting with

Voxe to complete structured tasks.(37, 38) The think-aloud technique is integral to

understanding the end-user experience with Voxe and will highlight potential barriers to Voxe

adoption that can inform its subsequent implementation.(37, 38) Semi-structured interviews

and data analytics, described below, will also be conducted.(39)

Study participants and inclusion criteria

Purposive sampling will be used to recruit 12 to 20 patient participants across age,

organ type, sex, gender, and ethnicity from the Transplant and Regenerative Medicine Centre

at SickKids. Twelve to 20 members of the patients' interdisciplinary healthcare team will also be

recruited purposively across professional disciplines, years of practice, sex, gender and

ethnicity.(21)

Patients eligible to participate will include those who are: (a) eight to 17 years of age

with capacity to assent/consent, (b) those able to speak and read English, (c) heart, kidney, liver

or lung transplant recipients, and (d) who are a minimum of three months post-transplant.

Informed consent will be obtained from the parents/legal guardians of participants who

provide assent. Eligible healthcare providers include any member of the interdisciplinary

healthcare team within the Transplant and Regenerative Medicine Centre at SickKids who have

worked within their position for a minimum of six months.

Procedures and outcomes

Following Phase 4, the development team will use the Voxe patient and healthcare

provider annotated wireframes to develop the respective interfaces of the Voxe ePROM

platform, using an agile, scrum framework.(19) Feature development will be phased and will

include authentication, user dashboards, account settings, privacy/security controls and survey

submission/review functionality.

Four rounds of iterative testing will be completed with three to five patients and three

to five healthcare providers per round, as is consistent with usability testing methods for clinical

information systems.(21) The first two rounds will be conducted in-person or virtual with a

member of the study team, using smartphones, tablets and/or computers. Both patient and

healthcare provider participants will be asked to complete a core set of tasks on Voxe which will

be presented to them in the form of scenarios that they may encounter while interacting with

Voxe. For example, patients will be provided with an anonymous username and password,

invited to successfully log into Voxe, and navigate Voxe to complete available ePROMs (i.e.

PedsQL™ Generic Core Scales(40)). Healthcare providers will be invited to navigate Voxe to

view and interpret sample ePROM results. Employing think-aloud methodology, participants

will be encouraged to voice out loud what they are looking at, thinking, doing and feeling as

they navigate the platform.(37, 39)

The last two testing rounds will be conducted to simulate 'real-world' settings.

An automated text message or email with an embedded hyperlink will be sent to patients

asking them to access Voxe remotely on a smartphone, tablet or computer. Patients will

independently log into Voxe using an anonymous username and password and navigate the

platform to complete available ePROMs. Healthcare providers will be asked to access Voxe on a

computer and independently navigate the Voxe platform to view and interpret ePROM data

entered by patients.

Objective measures to be collected include: (1) participant compliance, (2) time on task,

(3) successful task completion (fidelity), (4) frequency of critical errors, (5) frequency of non-

critical errors, and (6) error-free rate.(41) Following each testing round, in-person or virtual

semi-structured interviews will be conducted to ascertain what participants liked or disliked

and why, ease of use, elements of functionality in the context of typical practice workflow, as

well as suggestions for improvements. Iterative usability testing will also be conducted until

Voxe is considered acceptable to participating end-users with no further refinements

identified.(35, 36) Interviews will be audio-recorded, transcribed verbatim and de-identified.

<u>Data analysis</u>

Quantitative data including participant compliance, time on task, successful task

completion, frequency of critical and non-critical errors, and error-free rate will be analyzed.

Similar to Phase 4, qualitative interviews will be subject to content and thematic analysis to

identify emerging themes.(31, 32) Themes will be coded and categorized using NVivo 12

according to type and frequency of occurrence.(34) Quantitative and qualitative data will be

triangulated to inform changes made to the Voxe platform.

Patient and public involvement

Phases 4 and 5 are informed by the invaluable feedback provided by stakeholders,

including pediatric patients, their caregivers and healthcare providers, from previous phases of

research.(16) Patients' and healthcare providers' thoughts, feelings and perspectives about

Voxe captured through research processes described in this protocol will continue to guide this

research program. Stakeholder involvement will ensure the implementation of evidence-based

interventions integral to achieving meaningful patient outcomes.

ETHICS AND DISSEMINATION

Ethics approval and consent to participate

Institutional research ethics board approval has been provided by SickKids (REB number: 1000057043 (Phase 4); REB number: 1000067700 (Phase 5)). All participants will provide informed consent or assent prior to their involvement in the study. For participants who provide informed assent, informed consent will be obtained from the parents/legal guardians prior to study participation.

Information security

All interviews will be audio recorded and transcribed verbatim. Transcription will be completed by a member of the study team. All transcriptions will be de-identified to protect participant confidentiality. All identifying information, both paper copy and electronic information, will be kept confidential. Use of data over the course of the study and dissemination of results will follow standard practice guidelines as determined by the SickKids Research Institute.

Discussion and dissemination

The collection of PROMs provides the opportunity to incorporate patient-centred perspectives into pediatric clinical practice.(2, 6, 11, 42-45) The creation of the Voxe ePROM platform will reform the practice of pediatric medicine by enhancing the capacity of patient-provider partnerships to identify and address issues that are most meaningful to patients.(46) The design and development of Voxe outlined in this protocol are critical to answering important methodological and operational questions that will inform the implementation of ePROMs in pediatric clinical settings.

Engaging patients and healthcare providers throughout Voxe design and development will result in the creation and launch of a user-centred ePROM platform. For patients, Voxe will facilitate ePROM data collection in a child friendly and patient-centred manner. For healthcare

providers, Voxe will facilitate convenient and timely review of patient ePROM data, collaboration within healthcare teams, and shared decision-making discussions between healthcare providers and patients during clinical encounters.

During Phase 4, patients and healthcare providers will share their likes and dislikes of the design and comment on Voxe functionality and ease of use. It is critical that Voxe design iterations integrate this feedback, as the interface needs to be designed in a way that is logical, intuitive, and user friendly for end-users. This process will ensure that there is an evidence-based iterative design in place before usability testing. In Phase 5, patients and healthcare providers will comment on what they liked or disliked about Voxe and why, Voxe ease of use, and elements of functionality in the context of typical practice workflow, as well as suggestions to improve Voxe. Voxe will be further refined according to this feedback until a final version is produced. The final product will enhance the experience of end-users with systematically tested functionality and design. Following the procedures outlined above, creating an evidence-based ePROM platform will enable these outcomes. Findings from this study will be widely disseminated through infographics, posts on the research team's website, peer-reviewed journal publications and presentations at patient and family educational events as well as scientific and academic conferences. Data collection is expected to be completed by the end of 2021 with publication of results in early 2022.

This research lays the groundwork for future investigations that will include Voxe healthcare provider orientation and competency training as part of a more comprehensive implementation plan. Additionally, an implementation-effectiveness evaluation (Phase 6) of the

Voxe ePROM platform will be conducted to explore how Voxe can be effectively implemented

in a manner that impacts pediatric transplantation patient's health outcomes and clinical care.

List of abbreviations
ePROM – Electronic patient-reported outcome measure
PROM – Patient-reported outcome measure

Acknowledgements
The authors thank our patient partners and past and future research participants.

Competing interests
The authors declare that they have no competing interests.

Funding
This study was supported by the SickKids Transplant and Regenerative Medicine Centre and Astellas Pilot Grant (Grant/Award Number: Not Applicable), the Canadian Donation and Transplantation Research Program Innovation Grant (Grant/Award Number: Not Applicable) and the Health Canada Health Care Policy Contribution Program (Grant/Award Number: 1920-HQ-000105).

Authors' contributions
All authors contributed to project conception and study design. SJA, SJP and JL drafted the manuscript. All authors read the manuscript and gave final approval of the version to be published.

References

1. Rossano JW, Cherikh WS, Chambers DC, et al. The international thoracic organ transplant registry of the International Society for Heart and Lung Transplantation: Twenty-first pediatric heart transplantation report—2018; Focus theme: Multiorgan transplantation. *J Heart Lung Transplant* 2018;37(10):1184-95.

2. Bevans KB, Moon J, Carle AC, et al. Patient reported outcomes as indicators of pediatric health care quality. *Acad Pediatr* 2014;14(5):S90-S96.

3. US Department of Health Human Services Food and Drug Administration. Guidance for industry - Patient-reported outcome measures: Use in medical product development to support labeling claims. *Fed Reg* 2009;74(235):65132–33.

4. Santana M-J, Feeny D. Framework to assess the effects of using patient-reported outcome measures in chronic care management. *Qual Life Res* 2014;23(5):1505-13.

5. Fung CH, Hays RD. Prospects and challenges in using patient-reported outcomes in clinical practice. *Qual Life Res* 2008;17(10):1297-302.

6. Bitton A, Onega T, Tosteson AN, et al. Toward a better understanding of patient-reported outcomes in clinical practice. *Am J Manag Care* 2014;20(4):281.

7. Nelson EC, Eftimovska E, Lind C, et al. Patient reported outcome measures in practice. *BMJ* 2015;350

8. Valderas J, Kotzeva A, Espallargues M, et al. The impact of measuring patient-reported outcomes in clinical practice: A systematic review of the literature. *Qual Life Res* 2008;17(2):179-93.

9. Forrest CB. Digitization of patient-reported outcomes. *Value Health* 2013;16(4):459-60. doi: 10.1016/j.jval.2013.05.005

10. McCurdie T, Taneva S, Casselman M, et al. mHealth consumer apps: The case for user-centered design. *Biomed Instrum Technol* 2012;46(Suppl 2):49-56.

11. Huang I-C, Revicki DA, Schwartz CE. Measuring pediatric patient-reported outcomes: Good progress but a long way to go: Springer, 2014.

12. Hoffmann T, Bennett S, Del Mar C. Evidence-based practice across the health professions-e-book: Elsevier Health Sciences 2013.

13. Aaronson N, Elliott T, Greenhalgh J, et al. User's guide to implementing patient-reported outcomes assessment in clinical practice version 2. In: Research ISfQoL, ed., 2015.

14. Anthony SJ, Stinson H, Lazor T, et al. Patient-reported outcome measures within pediatric solid organ transplantation: A systematic review. *Pediatr Transplant* 2019;23(6):e13518.

15. Terwee CB, Mokkink LB, Knol DL, et al. Rating the methodological quality in systematic reviews of studies on measurement properties: A scoring system for the COSMIN checklist. *Qual Life Res* 2012;21(4):651-57.

16. Anthony SJ, Young K, Pol SJ, et al. Patient-reported outcome measures in pediatric solid organ transplantation: Exploring stakeholder perspectives on clinical implementation through qualitative description. *Qual Life Res* 2021 doi: 10.1007/s11136-020-02743-8 [published Online First: 2021/01/16]

17. Meyers DC, Durlak JA, Wandersman A. The quality implementation framework: A synthesis of critical steps in the implementation process. *Am J Community Psychol* 2012;50(3-4):462-80.

18. Verhoeven F, Tanja-Dijkstra K, Nijland N, et al. Asynchronous and synchronous teleconsultation for diabetes care: A systematic literature review. *J Diabetes Sci Technol* 2010;4(3):666-84.

19. Barnum CM. Chapter 1: Establishing the essentials. In: Merken S, ed. Usability testing essentials: ready, set test! 2 ed. Amsterdam: Elsevier 2020:9-33.

20. Palinkas LA, Horwitz SM, Green CA, et al. Purposeful sampling for qualitative data collection and analysis in mixed method implementation research. *Adm Policy Ment Health* 2015;42(5):533-44. doi: 10.1007/s10488-013-0528-y

21. Kushniruk AW, Patel VL. Cognitive and usability engineering methods for the evaluation of clinical information systems. *J Biomed Inform* 2004;37(1):56-76.

22. International Organization for Standardization. ISO 9241-11:2018(en) Ergonomics of human-system interaction — Part 11: Usability: Definitions and concepts 2018 [Available from: https://www.iso.org/obp/ui/#iso:std:iso:9241:-11:ed-2:v1:en accessed January 20 2021.

23. International Organization for Standardization. About us: What we do [Available from: https://www.iso.org/what-we-do.html accessed January 20 2021.

24. Barnum CM. Chapter 8: Analyzing the findings. In: Merken S, ed. Usability testing essentials: ready, set test! 2 ed. Amsterdam: Elsevier 2020:287-319.

25. International Organization for Standardization. ISO 9000:2015(en) Quality management systems — Fundamentals and vocabulary 2015 [Available from: https://www.iso.org/obp/ui/#iso:std:iso:9000:ed-4:v1:en accessed January 20 2021.

26. Barnum C. Chapter 6: Preparing for usability testing. In: Merken S, ed. Usability testing essentials: ready, set test! 2 ed. Amsterdam: Elsevier 2020:197-248.

27. Benedek J, Miner T. Measuring desirability: New methods for evaluating desirability in a usability lab setting. *Usability Professionals Association* 2002;2003(8-12):57.

28. Galletta A. Mastering the semi-structured interview and beyond: From research design to analysis and publication: NYU Press 2013.

29. Rubin HJ, Rubin IS. Qualitative interviewing: The art of hearing the data. 2 ed. Thousand Oaks, CA: SAGE 2005.

30. Kallio H, Pietilä AM, Johnson M, et al. Systematic methodological review: Developing a framework for a qualitative semi-structured interview guide. *J Adv Nurs* 2016;72(12):2954-65.

31. Gibbs G. Analysing qualitative data. London, England: SAGE 2007.

32. Fereday J, Muir-Cochrane E. Demonstrating rigor using thematic analysis: A hybrid approach of inductive and deductive coding and theme development. *Int J Qual Methods* 2006;5(1):80-92.

33. Elo S, Kyngäs H. The qualitative content analysis process. *J Adv Nurs* 2008;62(1):107-15. doi: 10.1111/j.1365-2648.2007.04569.x [published Online First: 2008/03/21]

34. Richards L. Using NVivo in qualitative research: Sage 1999.

35. Stinson JN, Jibb LA, Nguyen C, et al. Development and testing of a multidimensional iPhone pain assessment application for adolescents with cancer. *J Med Internet Res* 2013;15(3):e51.

36. Macefield R. How to specify the participant group size for usability studies: A practitioner's guide. *J Usability Stud* 2009;5(1):34-45.

37. Li AC, Kannry JL, Kushniruk A, et al. Integrating usability testing and think-aloud protocol analysis with "near-live" clinical simulations in evaluating clinical decision support. *Int J Med Inform* 2012;81(11):761-72.

38. Rose AF, Schnipper JL, Park ER, et al. Using qualitative studies to improve the usability of an EMR. *J Biomed Inform* 2005;38(1):51-60.

39. Lewis C. Using the "think aloud" method in cognitive interface design. *New York: IBM* 1982

40. Varni J, Seid M, Kurtin P. PedsQL TM 4.0: Reliability and validity of the Pediatric Quality of Life Inventory TM Version 4.0 Generic Core Scales in healthy and patient populations. *Med Care* 2001;39:800-12.

41. US General Services Administration Technology Transformation Services. Planning a Usability Test 2021 [Available from: https://www.usability.gov/how-to-and-tools/methods/planning-usability-testing.html accessed January 20 2021.

42. Calvert M, Kyte D, Price G, et al. Maximising the impact of patient reported outcome assessment for patients and society. *BMJ* 2019;364

43. Haverman L, Engelen V, van Rossum MA, et al. Monitoring health-related quality of life in paediatric practice: Development of an innovative web-based application. *BMC Pediatr* 2011;11(1):1-7.

44. Haywood K, Brett J, Salek S, et al. Patient and public engagement in health-related quality of life and patient-reported outcomes research: What is important and why should we care? Findings from the first ISOQOL patient engagement symposium. *Qual Life Res* 2015;24(5):1069-76.

45. Cleemput I, Dobbels F. Measuring patient-reported outcomes in solid organ transplant recipients. *Pharmacoeconomics* 2007;25(4):269-86.

46. Engelen V, Detmar S, Koopman H, et al. Reporting health-related quality of life scores to physicians during routine follow-up visits of pediatric oncology patients: Is it effective? *Pediatr Blood Cancer* 2012;58(5):766-74.

Figure 1: Measuring What Matters: Implementing Patient-Reported Outcome Measures into Clinical Practice – A Research Program

GUIDED – a guideline for reporting for intervention development studies.

Supplementary File 1: Blank Checklist

Item description	Explanation	Page in manuscript where item is located	Other*
1. Report the context for which the intervention was developed.	Understanding the context in which an intervention was developed informs readers about the suitability and transferability of the intervention to the context in which they are considering evaluating, adapting or using the intervention. Context here can include place, organisational and wider socio-political factors that may influence the development and/or delivery of the intervention (15).	9, 10, 13, 14	
2. Report the purpose of the intervention development process.	Clearly describing the purpose of the intervention specifies what it sets out to achieve. The purpose may be informed by research priorities, for example those identified in systematic reviews, evidence gaps set out in practice guidance such as The National Institute for Health and Care Excellence or specific prioritisation exercises such as those undertaken with patients and practitioners through the James Lind Alliance.	8	
3. Report the target population for the intervention development process.	The target population is the population that will potentially benefit from the intervention – this may include patients, clinicians, and/or members of the public. If the target population is clearly described then readers will be able to understand the relevance of the intervention to their own research or practice. Health inequalities, gender and ethnicity are features of the target population that may be relevant to intervention development processes.	9, 10, 13, 14	
4. Report how any published intervention development approach contributed to the development process	Many formal intervention development approaches exist and are used to guide the intervention development process (e.g. 6Squid (16) or The Person Based Approach to Intervention Development (17)). Where a formal intervention development approach is used, it is helpful to describe the process that was followed, including any deviations. More general approaches to intervention development also exist and have been categorised as follows (3):- Target Population-centred intervention development; evidence and theory-based intervention development; partnership intervention development; implementation-based intervention development; efficacy-based intervention development; step or phased-based intervention development; and intervention-specific intervention development (3). These approaches do not always have specific guidance that describe their use. Nevertheless, it is helpful to give a rich description of how any published approach was operationalised	9, 13, 14	
5. Report how evidence from different sources informed the intervention development process.	Intervention development is often based on published evidence and/or primary data that has been collected to inform the intervention development process. It is useful to describe and reference all forms of evidence and data that have informed the development of the intervention because evidence bases can change rapidly, and to explain the manner in which the evidence and/or data was used. Understanding what evidence was and was not available at the time of intervention development can help readers to assess transferability to their current situation.	6-8	
6. Report how/if published theory informed the intervention development process.	Reporting whether and how theory informed the intervention development process aids the reader's understanding of the theoretical rationale that underpins the intervention. Though not mentioned in the e-Delphi or consensus meeting, it became increasingly apparent through the development of our guidance that this theory item could relate to either existing published theory or programme theory	5, 6, 9, 13, 14	
7. Report any use of components from an existing intervention in the current intervention development process.	Some interventions are developed with components that have been adopted from existing interventions. Clearly identifying components that have been adopted or adapted and acknowledging their original source helps the reader to understand and distinguish between the novel and adopted components of the new intervention.	5, 6	
8. Report any guiding principles, people or factors that were prioritised when making decisions during the intervention development process.	Reporting any guiding principles that governed the development of the application helps the reader to understand the authors' reasoning behind the decisions that were made. These could include the examples of particular populations who views are being considered when designing the intervention, the modality that is viewed as being most appropriate, design features considered important for the target population, or the potential for the intervention to be scaled up.	5-8	

1

Item description	Explanation	Page in manuscript where item is located	Other*
9. Report how stakeholders contributed to the intervention development process.	Potential stakeholders can include patient and community representatives, local and national policy makers, health care providers and those paying for or commissioning health care. Each of these groups may influence the intervention development process in different ways. Specifying how differing groups of stakeholders contributed to the intervention development process helps the reader to understand how stakeholders were involved and the degree of influence they had on the overall process. Further detail on how to integrate stakeholder contributions within intervention reporting are available (19).	6-11, 13-15	
10. Report how the intervention changed in content and format from the start of the intervention development process.	Intervention development is frequently an iterative process. The conclusion of the initial phase of intervention development does not necessarily mean that all uncertainties have been addressed. It is helpful to list remaining uncertainties such as the intervention intensity, mode of delivery, materials, procedures, or type of location that the intervention is most suitable for. This can guide other researchers to potential future areas of research and practitioners about uncertainties relevant to their healthcare context.	N/A	
11. Report any changes to interventions required or likely to be required for subgroups.	Specifying any changes that the intervention development team perceive are required for the intervention to be delivered or tailored to specific sub groups enables readers to understand the applicability of the intervention to their target population or context. These changes could include changes to personnel delivering the intervention, to the content of the intervention, or to the mode of delivery of the intervention.	N/A	
12. Report important uncertainties at the end of the intervention development process.	Intervention development is frequently an iterative process. The conclusion of the initial phase of intervention development does not necessarily mean that all uncertainties have been addressed. It is helpful to list remaining uncertainties such as the intervention intensity, mode of delivery, materials, procedures, or type of location that the intervention is most suitable for. This can guide other researchers to potential future areas of research and practitioners about uncertainties relevant to their healthcare context.	N/A	
13. Follow TIDieR guidance when describing the developed intervention.	Interventions have been poorly reported for a number of years. In response to this, internationally recognized guidance has been published to support the high quality reporting of health care? interventions[5] and public health interventions[14]. This guidance should therefore be followed when describing a developed intervention.	N/A	
14. Report the intervention development process in an open access format.	Unless reports of intervention development are available people considering using an intervention cannot understand the process that was undertaken and make a judgement about its appropriateness to their context. It also limits cumulative learning about intervention development methodology and observed consequences at later evaluation, translation and implementation stages. Reporting intervention development in an open access (Gold or Green) publishing format increases the accessibility and visibility of intervention development research and makes it more likely to be read and used. Potential platforms for open access publication of intervention development include open access journal publications, freely accessible funder reports or a study web-page that details the intervention development process.	N/A	

*e.g. if item is reported elsewhere, then the location of this information can be stated here.

BMJ Open

The creation of an electronic patient-reported outcome measure platform Voxe: A mixed methods study protocol in pediatric solid organ transplantation

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BMJ

I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our licence.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which Creative Commons licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1

Title

The creation of an electronic patient-reported outcome measure platform Voxe: A mixed methods study protocol in pediatric solid organ transplantation

Authors

Samantha J. Anthony[1-4], Sarah J. Pol[1], Jia Lin[1], Melanie Barwick[1,5,6], Michael Brudno[7,8], Dorin Manase[7], Rulan S. Parekh[1,2,9,10], Amanda Silva[7], Jennifer Stinson[1,11]

1. Child Health Evaluative Sciences, Peter Gilgan Centre for Research and Learning, The Hospital for Sick Children, Toronto, ON, Canada
2. Transplant and Regenerative Medicine Centre, The Hospital for Sick Children, Toronto, ON, Canada
3. Factor-Inwentash Faculty of Social Work, University of Toronto, Toronto, ON, Canada
4. Canadian Donation and Transplantation Research Program, Edmonton, AB, Canada
5. Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada
6. Temerty Faculty of Medicine, Department of Psychiatry, University of Toronto, Toronto, ON, Canada
7. Data Aggregation, Translation and Architecture, University Health Network, Toronto, ON, Canada
8. Faculty of Arts and Science, Department of Computer Science, University of Toronto, Toronto, ON, Canada
9. Division of Nephrology, The Hospital for Sick Children, Toronto, ON, Canada
10. Division of Nephrology, University Health Network, Toronto, ON, Canada
11. Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, ON, Canada

Author	ORCID
Samantha J. Anthony	0000-0002-1800-2333
Sarah J. Pol	0000-0003-1883-1753
Jia Lin	0000-0002-8691-3358
Melanie Barwick	0000-0002-2478-604X
Michael Brudno	0000-0001-7947-2243
Rulan S. Parekh	0000-0001-6313-5752
Jennifer Stinson	0000-0002-9969-8052

Corresponding author

Samantha J. Anthony

The Hospital for Sick Children

686 Bay Street, Toronto, Ontario, M5G 0A4

E-mail: samantha.anthony@sickkids.ca

Word count: 3386

2

Abstract
Introduction:

Patient-reported outcome measures (PROMs) provide an opportunity for meaningful patient engagement and shared decision-making. The objective of this research program is to improve health outcomes for pediatric solid organ transplant patients by implementing PROMs into clinical care. The current study aims to create Voxe, a pediatric user-centred electronic PROM platform, by engaging pediatric patients and healthcare providers throughout the design and development process.

Methods and analysis:

The creation of Voxe will occur over two phases that build on previous research. The user interface design phase will employ a 'user-centric' approach to identify end-users' needs and iteratively refine the look and layout of Voxe to meet these needs. Transplant recipients and healthcare providers will participate in three rounds of testing. During virtual sessions, participants will: (1) complete task-based activities (outcomes – effectiveness and efficiency), (2) complete questionnaires (outcome – satisfaction), and (3) participate in a semi-structured interview. The following phase will involve software development and Voxe usability testing. Transplant recipients and healthcare providers will participate in four rounds of iterative testing. The think-aloud technique will be employed, and participants will describe their thoughts and feelings while interacting with a Voxe prototype to complete structured tasks. Participants will: (1) log into Voxe and complete tasks (outcomes – time on task, successful task completion, frequency of critical and non-critical errors and error-free rate), and (2) participate in a semi-structured interview. Findings will result in the creation and launch of a user-centred electronic PROM platform prototype.

3

Ethics and dissemination:

Research ethics board approval has been provided by The Hospital for Sick Children. This

research is critical to answering methodological and operational questions that will inform Voxe

implementation in pediatric clinical settings and facilitate PROM data collection. Future

investigations will include an implementation-effectiveness evaluation of the Voxe platform.

<u>**Article Summary – Strengths and limitations of this study**</u>

- By engaging pediatric patients and healthcare providers throughout the design and

  development process, this study will facilitate the creation and launch of an evidence-

  based pediatric user-centred electronic PROM platform prototype called Voxe

- A 'user-centric' approach will consider the needs of pediatric patients and healthcare

  providers at each design phase and allow for iterative modification of wireframes to

  best meet their identified needs.

- The think-aloud technique will facilitate understanding of the end-user's experience

  with Voxe by enabling participants to verbalize their thoughts and feelings while

  interacting with Voxe to complete specific tasks.

- As the ability to speak and read English is a requirement for study participation, the

  perspectives of those who are not able to speak and read English will be missed in these

  phases of the study.

- This study builds the foundation for future phases of research which will include

  healthcare provider Voxe orientation and competency training and an implementation-

  effectiveness evaluation.

4

Keywords

- Quality in health care

- Transplant medicine

- Mental health

- Paediatrics

- Paediatric transplant surgery

- Qualitative research

5

BACKGROUND

For children with end-stage organ failure, transplantation is a life-saving therapy.(1, 2) However, evaluating the success of solid organ transplantation based solely on objective clinical outcomes is insufficient. The patient's subjective assessment is a crucial component in evaluating the burden of disease and can be captured via patient-reported outcome measures (PROMs).(1, 2) PROMs are defined as: "any report of the patient's health condition that comes directly from the patient, without interpretation of the patient's response by a clinician or anyone else" (pg. 2).(3) PROMs can capture a patient's self-assessment of functional status, symptoms, treatment adherence, and multiple domains of well-being and quality of life.(4, 5) In doing so, PROMs give patients a voice in their healthcare and provide an opportunity for meaningful engagement.(6) Research indicates that the systematic collection of PROM data enhances patient-clinician communication and shared decision-making, thereby improving health outcomes.(4, 5, 7, 8) The inclusion of PROMs in clinical care assists in identifying valuable information about the impact of transplantation on patients' symptoms as well as their functional and emotional status. This in turn may help healthcare providers to detect under- and unrecognized problems (e.g., depression, anxiety), resulting in more effective patient care (e.g., initiation of clinical interventions) and an efficient healthcare system.

Innovative opportunities to integrate PROMs into clinical practice have been buoyed by recent advances in eHealth.(9, 10) In particular, the development and implementation of electronic PROMs (ePROMs) can help identify important, patient-valued concerns at the point of care, supporting the delivery of appropriate and timely interventions. Moreover, current platforms that support the use of ePROMs are underdeveloped and require better

6

implementation with clinical care.(2, 6, 7) Further, research on the implementation

effectiveness of ePROMs in pediatric clinical settings is limited,(2, 11) giving rise to concerns

that ePROMs may languish, unused, and fail to realize meaningful outcomes for patients.

Implementation of evidence-based interventions is important to ensure meaningful patient

outcomes.(12) Achieving optimal clinical and health system outcomes for ePROMS will require

more intentional and explicit study of how they might best be implemented prior to

widespread implementation.(1, 2, 5)

The overarching objective of this research program is to improve health outcomes and

transform the delivery of care for pediatric transplant patients in Canada by integrating

ePROMs into standard clinical practice. This program of research uses a phased approach to

target the methodological and practical decisions (e.g., determining which standardized PROMs

to use, identifying goals for collecting PROMs, selecting patients, setting, and timing of

assessment, etc.) needed to guide systematic and effective implementation of ePROMs into

'real-world' pediatric patient care settings.(13) Recently completed foundational research to

explore these questions within pediatric solid organ transplantation consisted of the three

phases of work outlined below.

Phase 1: Systematic review

A systematic review was conducted to identify PROMs used in pediatric solid organ

transplantation.(14) A total of 4,305 studies were identified, of which 62 describing 47 PROMs

were selected for analysis and were appraised for adherence to internationally recommended

guidelines for item generation, item reduction, and psychometric properties.(15) Findings

revealed six standardized PROMs that had undergone psychometric evaluation in a pediatric

solid organ transplant population. This phase of work identified standardized PROMs to consider for implementation into clinical care.

Phase 2: Interviews with key stakeholders

Interviews with key stakeholders across Canada, including: (a) pediatric solid organ transplant recipients, (b) parent(s)/caregiver(s), and (c) healthcare providers, were conducted to explore perspectives regarding ePROMs implementation into clinical practice.(16) Sixty-three participants across five Canadian pediatric transplant centres were interviewed, among whom nearly all (60/63; 95%) were supportive of implementing an ePROM system into clinical practice with the primary goals of: (1) integrating the transplant patient's overall well-being into the clinical care conversation, (2) capturing the patient's voice and increasing patient engagement, and (3) informing pediatric transplant clinical care. Insights for effective PROM implementation included the remote completion of ePROMs in advance of clinical appointments for patients eight to 10 years of age or older.

Phase 3: Consensus workshop

A two-day consensus workshop was hosted in December 2018 in Toronto to further explore how ePROMs could best be implemented into pediatric transplant clinical practice. Workshop proceedings were informed by the results of Phases 1 and 2. The workshop was attended by 25 leading experts in the fields of pediatric solid organ transplantation, PROMs, implementation science, and computational medicine, as well as patients, caregivers, healthcare providers, researchers, and administrators from across Canada. Workshop outcomes included: (1) consensus on key methodological and operational decisions for implementing ePROMs into practice (e.g. which standardized PROMS to utilize, the setting and timing of

8

assessment, as well as the mode for administering ePROMs), (2) a research plan to design,

develop and evaluate the usability and implementation of an ePROM platform, and (3) a

knowledge translation strategy to disseminate research findings to key knowledge users (e.g.

newsletter, peer-reviewed publications, website posting, national and international

presentations). The consensus workshop captured attendees' perspectives on practice and

systems-based facilitators and barriers to implementing ePROMs and was instrumental in

ensuring that future research would be relevant and meaningful to stakeholders.

Study objectives

Results from Phases 1 to 3 inform the current study, Phases 4 and 5.(17) The

overarching aim of the proposed study, which will be conducted within the Transplant and

Regenerative Medicine Centre at The Hospital for Sick Children (SickKids), is to create an

ePROM platform called Voxe, that will capture and implement patient-reported outcomes into

the clinical care workflow for pediatric organ transplant patients. Specifically, Phase 4 aims to

design the user interfaces of the Voxe platform, and Phase 5 aims to develop the Voxe software

and conduct usability testing of Voxe in preparation for a future implementation-effectiveness

trial (Phase 6). A graphical representation of the different research phases is displayed in Figure

1: *Measuring What Matters: Implementing Patient-Reported Outcome Measures into Clinical*

Practice – A Research Program.

9

METHODS

Phase 4: User interface design of Voxe ePROM platform

eHealth technologies designed and developed based on assumptions of end-user motivations, goals or needs, are often less effective than those that engage end-users throughout the process.(10, 18) Thus, a 'user-centric' approach in which end-users (i.e., patients and healthcare providers) are central to the design process will guide the design and development of Voxe. This evidence-based approach will consider the needs of Voxe users at each design phase and will allow for iterative modification of wireframes, which are the static, two-dimensional visual representation or layout of Voxe, to best meet their identified needs.(19-21) A 'user-centric' approach is paramount for user engagement with the platform, ultimately contributing to the effectiveness of the platform itself.(10)

Study participants and inclusion criteria

Purposive sampling will be used to recruit 12 patient participants across age, organ type, sex, gender, and ethnicity from the Transplant and Regenerative Medicine Centre at SickKids to obtain maximum variation.(22) Twelve members of the patients' interdisciplinary healthcare teams at SickKids will also be recruited purposively across professional disciplines, years of practice, sex, gender and ethnicity. This sample size is consistent with testing methods for clinical information systems.(23)

Patients eligible to participate include those who are: (a) 10 to 17 years of age, (b) able to speak and read English, and (c) heart, kidney, liver or lung transplant recipients who are a minimum of three months post-transplant. Patients with significant cognitive impairments, as determined by a healthcare team member, will not be invited to participate. Eligible healthcare

providers include any member of the interdisciplinary healthcare team within the Transplant and Regenerative Medicine Centre at SickKids.

Procedures and outcomes

The design of preliminary Voxe wireframes will be guided by: (1) stakeholder input gleaned from previous phases of research,(14, 16) and (2) design workshop processes, including identification of Voxe users (i.e., patients and healthcare providers) and the tasks they will complete on their respective platforms (i.e., persona and task inventory development). Following the design of preliminary wireframes, a rapid and iterative testing methodology will be used to evaluate, learn and improve Voxe prior to development (i.e., coding and launch).(19) Three rounds of testing sessions will be scheduled with patient and healthcare provider participants to elicit feedback on Voxe design features. Written consent and assent, as well as demographic information, will be obtained prior to study participation.

Each testing session will be conducted virtually via the Personal Health Information Protection Act-compliant version of Zoom or Microsoft Teams. During each session, International Organization for Standardization key performance indicators, consensus-base standards for technology, will be benchmarked and tracked to validate each iteration for success.(24, 25) In particular, objective and subjective standards common in user experience design testing,(26) will be collected to measure: (1) effectiveness – accuracy and completeness with which users achieve specific goals, displayed as a percentage of tasks successfully completed by users, and (2) efficiency – resources used in relation to results achieved, represented by the time it takes users to successfully complete the task.(27) Prior to the scheduled testing session, the URL for the testing website will be emailed to the participant.

1

During the session, participants will complete task-based activities using incremental segments (i.e., wireframes) of the Voxe platform.

Following the task-based activities, healthcare provider participants will complete a Likert scale questionnaire to assess the key performance indicator satisfaction. Patient participant's overall impression and experience with the Voxe platform will be evaluated using the Microsoft Desirability Toolkit.(28) Patient participants will select five words from a list of product reaction words to describe their attitude towards the Voxe platform. Product reaction words, such as "fun" and "calm" describe intangible emotional response towards the interface.(29)

Lastly, participants will share their likes and dislikes of the Voxe platform design and comment on the platform's ease of use and elements of functionality during a virtual semi-structured qualitative interview. Semi-structured interviews foster reciprocity between the participant and interviewer, allow the interviewer to ask pertinent follow-up questions to elicit rich data and enable the participant to express themselves using their own words.(30-32) The interview guide will be developed by the study team and will be informed by clinical knowledge and experience. Interviews will be conducted by study team members trained in qualitative methods. Sessions will be audio-recorded, transcribed verbatim and de-identified to protect participant confidentiality. Recruitment for Phase 4 began in May 2020.

Data analysis

Data collected during the testing sessions, including objective and subjective International Organization for Standardization key performance indicators, will be used to refine Voxe. The research team will utilize content and thematic analysis to categorize the data

1

collected during qualitative interviews.(33-35) Two members of the study team experienced in

qualitative methods, will code the data independently, and categories will be reviewed and

refined until consensus is reached for emerging themes. Trustworthiness will be achieved by

facilitating member checking and soliciting rich description during interviews, as well as hosting

frequent team meetings to support in-depth, iterative analysis with reflexive discussion among

team members. Analysis will be complete once the research team agrees that thematic

saturation is attained.(35) NVivo 12 will be used to manage qualitative data.(36) Quantitative

data collected during the testing sessions will be triangulated with qualitative themes to

provide a richer understanding of end-users' experience with Voxe. Refinements will be made

to the Voxe platform design based on the triangulated data. Three rounds of iterative feedback

testing will be conducted with each participant population (i.e. four participants per round)

until Voxe is considered acceptable to participating end-users with no further refinements

identified.(37, 38) Following the third round of patient and healthcare provider iterative testing,

the design team will share the final Voxe patient and healthcare provider annotated wireframes

with the development team.

Phase 5: Development of ePROM platform Voxe and usability testing

Usability is defined as the "extent to which a system, product or service can be used by

specified users to achieve specified goals with effectiveness, efficiency and satisfaction in a

specified context of use".(24) To test Voxe usability, the think-aloud technique will be

employed in which participants will verbalize their thoughts and feelings while interacting with

Voxe to complete structured tasks.(39, 40) The think-aloud technique is integral to

understanding the end-user experience with Voxe and will highlight potential barriers to Voxe

adoption that can inform its subsequent implementation.(39, 40) Semi-structured interviews

and data analytics, described below, will also be conducted.(41)

Study participants and inclusion criteria

Purposive sampling will be used to recruit 12 to 20 patient participants across age,

organ type, sex, gender, and ethnicity from the Transplant and Regenerative Medicine Centre

at SickKids. Twelve to 20 members of the patients' interdisciplinary healthcare team will also be

recruited purposively across professional disciplines, years of practice, sex, gender and

ethnicity.(23)

Patients eligible to participate will include those who are: (a) eight to 17 years of age

with capacity to assent/consent, (b) those able to speak and read English, (c) heart, kidney, liver

or lung transplant recipients, and (d) who are a minimum of three months post-transplant.

Informed consent will be obtained from the parents/legal guardians of participants who

provide assent. Eligible healthcare providers include any member of the interdisciplinary

healthcare team within the Transplant and Regenerative Medicine Centre at SickKids who have

worked within their position for a minimum of six months.

Procedures and outcomes

Following Phase 4, the development team will use the Voxe patient and healthcare

provider annotated wireframes to develop the respective interfaces of the Voxe ePROM

platform, using an agile, scrum framework.(19) A scrum framework is a project management

process within a hybrid software development model that applies a flexible development

process and places the needs of system end-users at the forefront to ensure that Voxe is both

useful and usable.(42, 43) The principles of iterative feedback, incremental development and

continual stakeholder involvement are central to this dynamic approach.(42, 43) Feature development will be phased and will include authentication, user dashboards, account settings, privacy/security controls and survey submission/review functionality.

Four rounds of iterative testing will be completed with three to five patients and three to five healthcare providers per round, as is consistent with usability testing methods for clinical information systems.(23) The first two rounds will be conducted in-person or virtual with a member of the study team, using smartphones, tablets and/or computers. Both patient and healthcare provider participants will be asked to complete a core set of tasks on Voxe which will be presented to them in the form of scenarios that they may encounter while interacting with Voxe. For example, patients will be provided with an anonymous username and password, invited to successfully log into Voxe, and navigate Voxe to complete available ePROMs (i.e. PedsQL™ Generic Core Scales(44)). Healthcare providers will be invited to navigate Voxe to view and interpret sample ePROM results. Employing think-aloud methodology, participants will be encouraged to voice out loud what they are looking at, thinking, doing and feeling as they navigate the platform.(39, 41)

The last two testing rounds will be conducted to simulate 'real-world' settings. An automated text message or email with an embedded hyperlink will be sent to patients asking them to access Voxe remotely on a smartphone, tablet or computer. Patients will independently log into Voxe using an anonymous username and password and navigate the platform to complete available ePROMs. Healthcare providers will be asked to access Voxe on a computer and independently navigate the Voxe platform to view and interpret ePROM data entered by patients.

1

Objective measures to be collected include: (1) time on task – the time it takes to complete each task, (2) successful task completion (fidelity) – when the end-user achieves the end goal of the task, (3) frequency of critical errors – a high severity error that could prevent an end-user from being able to complete a task, (4) frequency of non-critical errors – a low severity error that could decrease the efficiency with which an end-user completes a task, and (5) error-free rate – the percentage of task completions that occurred without any errors.(45, 46) Following each testing round, in-person or virtual semi-structured interviews will be conducted to ascertain what participants liked or disliked and why, ease of use, elements of functionality in the context of typical practice workflow, as well as suggestions for improvements. Iterative usability testing will also be conducted until Voxe is considered acceptable to participating end-users with no further refinements identified.(37, 38) Interviews will be audio-recorded, transcribed verbatim and de-identified.

<u>Data analysis</u>

Quantitative data including time on task, successful task completion, frequency of critical and non-critical errors, and error-free rate will be analyzed and descriptive statistics will be produced. Similar to Phase 4, qualitative interviews will be subject to content and thematic analysis to identify emerging themes.(33, 34) Themes will be coded and categorized using NVivo 12 according to type and frequency of occurrence.(36) Quantitative and qualitative data will be triangulated to inform changes made to the Voxe platform.

Patient and public involvement

Phases 4 and 5 are informed by the invaluable feedback provided by stakeholders, including pediatric patients, their caregivers and healthcare providers, from previous phases of

1

research.(16) Patients' and healthcare providers' thoughts, feelings and perspectives about Voxe captured through research processes described in this protocol will continue to guide this research program. Stakeholder involvement will ensure the implementation of evidence-based interventions integral to achieving meaningful patient outcomes.

ETHICS AND DISSEMINATION

Ethics approval and consent to participate

Institutional research ethics board approval has been provided by SickKids (REB number: 1000057043 (Phase 4); REB number: 1000067700 (Phase 5)). All participants will provide informed consent or assent prior to their involvement in the study. For participants who provide informed assent, informed consent will be obtained from the parents/legal guardians prior to study participation.

Information security

All interviews will be audio recorded and transcribed verbatim. Transcription will be completed by a member of the study team. All transcriptions will be de-identified to protect participant confidentiality. All identifying information, both paper copy and electronic information, will be kept confidential. Use of data over the course of the study and dissemination of results will follow standard practice guidelines as determined by the SickKids Research Institute.

Discussion and dissemination

The collection of PROMs provides the opportunity to incorporate patient-centred perspectives into pediatric clinical practice.(2, 6, 11, 47-50) The creation of the Voxe ePROM platform will reform the practice of pediatric medicine by enhancing the capacity of patient-provider partnerships to identify and address issues that are most meaningful to patients.(51)

1

The design and development of Voxe outlined in this protocol are critical to answering

important methodological and operational questions that will inform the implementation of

ePROMs in pediatric clinical settings.

Engaging patients and healthcare providers throughout Voxe design and development

will result in the creation and launch of a user-centred ePROM platform. For patients, Voxe will

facilitate ePROM data collection in a child friendly and patient-centred manner. For healthcare

providers, Voxe will facilitate convenient and timely review of patient ePROM data,

collaboration within healthcare teams, and shared decision-making discussions between

healthcare providers and patients during clinical encounters.

During Phase 4, patients and healthcare providers will share their likes and dislikes of

the design and comment on Voxe functionality and ease of use. It is critical that Voxe design

iterations integrate this feedback, as the interface needs to be designed in a way that is logical,

intuitive, and user friendly for end-users. This process will ensure that there is an evidence-

based iterative design in place before usability testing. In Phase 5, patients and healthcare

providers will comment on what they liked or disliked about Voxe and why, Voxe ease of use,

and elements of functionality in the context of typical practice workflow, as well as suggestions

to improve Voxe. Voxe will be further refined according to this feedback until a final version is

produced. The final product will enhance the experience of end-users with systematically

tested functionality and design. Following the procedures outlined above, creating an evidence-

based ePROM platform will enable these outcomes. Findings from this study will be widely

disseminated through infographics, posts on the research team's website, peer-reviewed

journal publications and presentations at patient and family educational events as well as

scientific and academic conferences. Data collection is expected to be completed by the end of

2021 with publication of results in early 2022.

This research lays the groundwork for future investigations that will include Voxe

healthcare provider orientation and competency training as part of a more comprehensive

implementation plan. Additionally, an implementation-effectiveness evaluation (Phase 6) of the

Voxe ePROM platform will be conducted to explore how Voxe can be effectively implemented

in a manner that impacts pediatric transplantation patient's health outcomes and clinical care.

List of abbreviations
ePROM – Electronic patient-reported outcome measure
PROM – Patient-reported outcome measure

Figure Caption
Figure 1: Measuring What Matters: Implementing Patient-Reported Outcome Measures into
Clinical Practice – A Research Program

Acknowledgements
The authors thank our patient partners and past and future research participants.

Competing interests
The authors declare that they have no competing interests.

Authors' contributions
All authors (SJA, SJP, JL, MBa, MBr, DM, RSP, AS, JS) contributed to project conception and
study design. SJA, SJP and JL drafted the manuscript. All authors (SJA, SJP, JL, MBa, MBr, DM,
RSP, AS, JS) read the manuscript and gave final approval of the version to be published.

References

1.   Rossano JW, Cherikh WS, Chambers DC, Goldfarb S, Hayes D, Khush KK, et al. The international thoracic organ transplant registry of the International Society for Heart and Lung Transplantation: Twenty-first pediatric heart transplantation report—2018; Focus theme: Multiorgan transplantation. J Heart Lung Transplant. 2018;37(10):1184-95.

2.   Bevans KB, Moon J, Carle AC, Mara CA, Lai J-S, DiMarco L, et al. Patient reported outcomes as indicators of pediatric health care quality. Acad Pediatr. 2014;14(5):S90-S6.

3.   US Department of Health Human Services Food and Drug Administration. Guidance for industry - Patient-reported outcome measures: Use in medical product development to support labeling claims. Fed Reg. 2009;74(235):65132–3.

4.   Santana M-J, Feeny D. Framework to assess the effects of using patient-reported outcome measures in chronic care management. Qual Life Res. 2014;23(5):1505-13.

5.   Fung CH, Hays RD. Prospects and challenges in using patient-reported outcomes in clinical practice. Qual Life Res. 2008;17(10):1297-302.

6.   Bitton A, Onega T, Tosteson AN, Haas JS. Toward a better understanding of patient-reported outcomes in clinical practice. Am J Manag Care. 2014;20(4):281.

7.   Nelson EC, Eftimovska E, Lind C, Hager A, Wasson JH, Lindblad S. Patient reported outcome measures in practice. BMJ. 2015;350.

8.   Valderas J, Kotzeva A, Espallargues M, Guyatt G, Ferrans C, Halyard M, et al. The impact of measuring patient-reported outcomes in clinical practice: A systematic review of the literature. Qual Life Res. 2008;17(2):179-93.

9.   Forrest CB. Digitization of patient-reported outcomes. Value Health. 2013;16(4):459-60.

10.   McCurdie T, Taneva S, Casselman M, Yeung M, McDaniel C, Ho W, et al. mHealth consumer apps: The case for user-centered design. Biomed Instrum Technol. 2012;46(Suppl 2):49-56.

11.   Huang I-C, Revicki DA, Schwartz CE. Measuring pediatric patient-reported outcomes: Good progress but a long way to go. Springer; 2014.

12.   Hoffmann T, Bennett S, Del Mar C. Evidence-based practice across the health professions-e-book: Elsevier Health Sciences; 2013.

13.   Aaronson N, Elliott T, Greenhalgh J, Halyard M, Hess R, Miller D, et al. User's guide to implementing patient-reported outcomes assessment in clinical practice version 2. 2015.

14.   Anthony SJ, Stinson H, Lazor T, Young K, Hundert A, Santana MJ, et al. Patient-reported outcome measures within pediatric solid organ transplantation: A systematic review. Pediatr Transplant. 2019;23(6):e13518.

15.   Terwee CB, Mokkink LB, Knol DL, Ostelo RW, Bouter LM, de Vet HC. Rating the methodological quality in systematic reviews of studies on measurement properties: A scoring system for the COSMIN checklist. Qual Life Res. 2012;21(4):651-7.

16.   Anthony SJ, Young K, Pol SJ, Selkirk EK, Blydt-Hansen T, Boucher S, et al. Patient-reported outcome measures in pediatric solid organ transplantation: Exploring stakeholder perspectives on clinical implementation through qualitative description. Qual Life Res. 2021.

17.   Meyers DC, Durlak JA, Wandersman A. The quality implementation framework: A synthesis of critical steps in the implementation process. Am J Community Psychol. 2012;50(3-4):462-80.

18.   Verhoeven F, Tanja-Dijkstra K, Nijland N, Eysenbach G, van Gemert-Pijnen L. Asynchronous and synchronous teleconsultation for diabetes care: A systematic literature review. J Diabetes Sci Technol. 2010;4(3):666-84.

19.   Barnum CM. Chapter 1: Establishing the essentials. In: Merken S, editor. Usability testing essentials: ready, set test! 2 ed. Amsterdam: Elsevier; 2020. p. 9-33.

20.   US General Services Administration Technology Transformation Services. Wireframing 2021 [Available from: https://www.usability.gov/how-to-and-tools/methods/wireframing.html.

21.   ProductPlan. Wireframe 2021 [Available from: https://www.productplan.com/glossary/wireframe/.

22.   Palinkas LA, Horwitz SM, Green CA, Wisdom JP, Duan N, Hoagwood K. Purposeful sampling for qualitative data collection and analysis in mixed method implementation research. Adm Policy Ment Health. 2015;42(5):533-44.

23.   Kushniruk AW, Patel VL. Cognitive and usability engineering methods for the evaluation of clinical information systems. J Biomed Inform. 2004;37(1):56-76.

24.   International Organization for Standardization. ISO 9241-11:2018(en) Ergonomics of human-system interaction — Part 11: Usability: Definitions and concepts 2018 [Available from: https://www.iso.org/obp/ui/#iso:std:iso:9241:-11:ed-2:v1:en.

25.   International Organization for Standardization. About us: What we do [Available from: https://www.iso.org/what-we-do.html.

26.   Barnum CM. Chapter 8: Analyzing the findings. In: Merken S, editor. Usability testing essentials: ready, set test! 2 ed. Amsterdam: Elsevier; 2020. p. 287-319.

27.   International Organization for Standardization. ISO 9000:2015(en) Quality management systems — Fundamentals and vocabulary 2015 [Available from: https://www.iso.org/obp/ui/#iso:std:iso:9000:ed-4:v1:en.

28.   Barnum C. Chapter 6: Preparing for usability testing. In: Merken S, editor. Usability testing essentials: ready, set test! 2 ed. Amsterdam: Elsevier; 2020. p. 197-248.

29.   Benedek J, Miner T. Measuring desirability: New methods for evaluating desirability in a usability lab setting. Usability Professionals Association. 2002;2003(8-12):57.

30.   Galletta A. Mastering the semi-structured interview and beyond: From research design to analysis and publication: NYU Press; 2013.

31.   Rubin HJ, Rubin IS. Qualitative interviewing: The art of hearing the data. 2 ed. Thousand Oaks, CA: SAGE; 2005.

32.   Kallio H, Pietilä AM, Johnson M, Kangasniemi M. Systematic methodological review: Developing a framework for a qualitative semi-structured interview guide. J Adv Nurs. 2016;72(12):2954-65.

33.   Gibbs G. Analysing qualitative data. London, England: SAGE; 2007.

34.   Fereday J, Muir-Cochrane E. Demonstrating rigor using thematic analysis: A hybrid approach of inductive and deductive coding and theme development. Int J Qual Methods. 2006;5(1):80-92.

35.   Elo S, Kyngäs H. The qualitative content analysis process. J Adv Nurs. 2008;62(1):107-15.

36.   Richards L. Using NVivo in qualitative research: Sage; 1999.

37.   Stinson JN, Jibb LA, Nguyen C, Nathan PC, Maloney AM, Dupuis LL, et al. Development and testing of a multidimensional iPhone pain assessment application for adolescents with cancer. J Med Internet Res. 2013;15(3):e51.

38.   Macefield R. How to specify the participant group size for usability studies: A practitioner's guide. J Usability Stud. 2009;5(1):34-45.

39.   Li AC, Kannry JL, Kushniruk A, Chrimes D, McGinn TG, Edonyabo D, et al. Integrating usability testing and think-aloud protocol analysis with "near-live" clinical simulations in evaluating clinical decision support. Int J Med Inform. 2012;81(11):761-72.

40.   Rose AF, Schnipper JL, Park ER, Poon EG, Li Q, Middleton B. Using qualitative studies to improve the usability of an EMR. J Biomed Inform. 2005;38(1):51-60.

41.   Lewis C. Using the "think aloud" method in cognitive interface design. New York: IBM. 1982.

42.   Cervone F. Understanding agile project management methods using scrum. OCLC Systems & Services International digital library perspectives. 2011;1(27):18-22.

43.   Brhel AM, H; Maedche, A; Werder, K. Exploring principles of user-centred agile software development: A literature review. Information and Software Technology. 2015(61):163-81.

44.   Varni J, Seid M, Kurtin P. PedsQL TM 4.0: Reliability and validity of the Pediatric Quality of Life Inventory TM Version 4.0 Generic Core Scales in healthy and patient populations. Med Care. 2001;39:800-12.

45.   US General Services Administration Technology Transformation Services. Planning a Usability Test 2021 [Available from: https://www.usability.gov/how-to-and-tools/methods/planning-usability-testing.html.

46.   Tullis TA, Bill. Chapter 4 – Performance Metrics. Measuring the User Experience. Second ed: Elsevier; 2013. p. 63–97.

47.   Calvert M, Kyte D, Price G, Valderas JM, Hjollund NH. Maximising the impact of patient reported outcome assessment for patients and society. BMJ. 2019;364.

48.   Haverman L, Engelen V, van Rossum MA, Heymans HS, Grootenhuis MA. Monitoring health-related quality of life in paediatric practice: Development of an innovative web-based application. BMC Pediatr. 2011;11(1):1-7.

49.   Haywood K, Brett J, Salek S, Marlett N, Penman C, Shklarov S, et al. Patient and public engagement in health-related quality of life and patient-reported outcomes research: What is important and why should we care? Findings from the first ISOQOL patient engagement symposium. Qual Life Res. 2015;24(5):1069-76.

50.   Cleemput I, Dobbels F. Measuring patient-reported outcomes in solid organ transplant recipients. Pharmacoeconomics. 2007;25(4):269-86.

51.   Engelen V, Detmar S, Koopman H, Maurice-Stam H, Caron H, Hoogerbrugge P, et al. Reporting health-related quality of life scores to physicians during routine follow-up visits of pediatric oncology patients: Is it effective? Pediatr Blood Cancer. 2012;58(5):766-74.

Figure 1: Measuring What Matters: Implementing Patient-Reported Outcome Measures into Clinical Practice – A Research Program

Phase 1 **Systematic Review** Completed	Phase 2 **Key Stakeholder Interviews** Completed	Phase 3 **Consensus Workshop** Completed	Phase 4 **Platform Design** In Progress	Phase 5 **Usability Testing**	Phase 6 **Implementation Effectiveness Trial**

GUIDED – a guideline for reporting for intervention development studies.

Supplementary File 1: Blank Checklist

Item description	Explanation	Page in manuscript where item is located	Other*
1. Report the context for which the intervention was developed.	Understanding the context in which an intervention was developed informs readers about the suitability and transferability of the intervention to the context in which they are considering evaluating, adapting or using the intervention. Context here can include place, organisational and wider socio-political factors that may influence the development and/or delivery of the intervention (15).	9, 10, 13, 14	
2. Report the purpose of the intervention development process.	Clearly describing the purpose of the intervention specifies what it sets out to achieve. The purpose may be informed by research priorities, for example those identified in systematic reviews, evidence gaps set out in practice guidance such as The National Institute for Health and Care Excellence or specific prioritisation exercises such as those undertaken with patients and practitioners through the James Lind Alliance.	8	
3. Report the target population for the intervention development process.	The target population is the population that will potentially benefit from the intervention – this may include patients, clinicians, and/or members of the public. If the target population is clearly described then readers will be able to understand the relevance of the intervention to their own research or practice. Health inequalities, gender and ethnicity are features of the target population that may be relevant to intervention development processes.	9, 10, 13, 14	
4. Report how any published intervention development approach contributed to the development process	Many formal intervention development approaches exist and are used to guide the intervention development process (e.g. 6Squid (16) or The Person Based Approach to Intervention Development (17)). Where a formal intervention development approach is used, it is helpful to describe the process that was followed, including any deviations. More general approaches to intervention development also exist and have been categorised as follows (3):- Target Population-centred intervention development; evidence and theory-based intervention development; partnership intervention development; implementation-based intervention development; efficacy-based intervention development; step or phased-based intervention development; and intervention-specific intervention development (3). These approaches do not always have specific guidance that describe their use. Nevertheless, it is helpful to give a rich description of how any published approach was operationalised	9, 13, 14	
5. Report how evidence from different sources informed the intervention development process.	Intervention development is often based on published evidence and/or primary data that has been collected to inform the intervention development process. It is useful to describe and reference all forms of evidence and data that have informed the development of the intervention because evidence bases can change rapidly, and to explain the manner in which the evidence and/or data was used. Understanding what evidence was and was not available at the time of intervention development can help readers to assess transferability to their current situation.	6-8	
6. Report how/if published theory informed the intervention development process.	Reporting whether and how theory informed the intervention development process aids the reader's understanding of the theoretical rationale that underpins the intervention. Though not mentioned in the e-Delphi or consensus meeting, it became increasingly apparent through the development of our guidance that this theory item could relate to either existing published theory or programme theory	5, 6, 9, 13, 14	
7. Report any use of components from an existing intervention in the current intervention development process.	Some interventions are developed with components that have been adopted from existing interventions. Clearly identifying components that have been adopted or adapted and acknowledging their original source helps the reader to understand and distinguish between the novel and adopted components of the new intervention.	5, 6	
8. Report any guiding principles, people or factors that were prioritised when making decisions during the intervention development process.	Reporting any guiding principles that governed the development of the application helps the reader to understand the authors' reasoning behind the decisions that were made. These could include the examples of particular populations who views are being considered when designing the intervention, the modality that is viewed as being most appropriate, design features considered important for the target population, or the potential for the intervention to be scaled up.	5-8	

1

Item description	Explanation	Page in manuscript where item is located	Other*
9. Report how stakeholders contributed to the intervention development process.	Potential stakeholders can include patient and community representatives, local and national policy makers, health care providers and those paying for or commissioning health care. Each of these groups may influence the intervention development process in different ways. Specifying how differing groups of stakeholders contributed to the intervention development process helps the reader to understand how stakeholders were involved and the degree of influence they had on the overall process. Further detail on how to integrate stakeholder contributions within intervention reporting are available (19).	6-11, 13-15	
10. Report how the intervention changed in content and format from the start of the intervention development process.	Intervention development is frequently an iterative process. The conclusion of the initial phase of intervention development does not necessarily mean that all uncertainties have been addressed. It is helpful to list remaining uncertainties such as the intervention intensity, mode of delivery, materials, procedures, or type of location that the intervention is most suitable for. This can guide other researchers to potential future areas of research and practitioners about uncertainties relevant to their healthcare context.	N/A	
11. Report any changes to interventions required or likely to be required for subgroups.	Specifying any changes that the intervention development team perceive are required for the intervention to be delivered or tailored to specific sub groups enables readers to understand the applicability of the intervention to their target population or context. These changes could include changes to personnel delivering the intervention, to the content of the intervention, or to the mode of delivery of the intervention.	N/A	
12. Report important uncertainties at the end of the intervention development process.	Intervention development is frequently an iterative process. The conclusion of the initial phase of intervention development does not necessarily mean that all uncertainties have been addressed. It is helpful to list remaining uncertainties such as the intervention intensity, mode of delivery, materials, procedures, or type of location that the intervention is most suitable for. This can guide other researchers to potential future areas of research and practitioners about uncertainties relevant to their healthcare context.	N/A	
13. Follow TIDieR guidance when describing the developed intervention.	Interventions have been poorly reported for a number of years. In response to this, internationally recognized guidance has been published to support the high quality reporting of health care interventions[5] and public health interventions[14]. This guidance should therefore be followed when describing a developed intervention.	N/A	
14. Report the intervention development process in an open access format.	Unless reports of intervention development are available people considering using an intervention cannot understand the process that was undertaken and make a judgement about its appropriateness to their context. It also limits cumulative learning about intervention development methodology and observed consequences at later evaluation, translation and implementation stages. Reporting intervention development in an open access (Gold or Green) publishing format increases the accessibility and visibility of intervention development research and makes it more likely to be read and used. Potential platforms for open access publication of intervention development include open access journal publications, freely accessible funder reports or a study web-page that details the intervention development process.	N/A	

*e.g. if item is reported elsewhere, then the location of this information can be stated here.

2

BMJ Open

The creation of an electronic patient-reported outcome measure platform Voxe: A mixed methods study protocol in pediatric solid organ transplantation

Journal:	*BMJ Open*
Manuscript ID	bmjopen-2021-053119.R2
Article Type:	Protocol
Date Submitted by the Author:	27-Sep-2021
Complete List of Authors:	Anthony, Samantha; The Hospital for Sick Children, Child Health Evaluative Sciences; University of Toronto, Factor-Inwentash Faculty of Social Work Pol, Sarah; The Hospital for Sick Children, Child Health Evaluative Sciences Lin, Jia; The Hospital for Sick Children, Child Health Evaluative Sciences Barwick, Melanie; The Hospital for Sick Children, Child Health Evaluative Sciences; University of Toronto, Dalla Lana School of Public Health Brudno, Michael; University Health Network, Data Aggregation, Translation and Architecture; University of Toronto, Faculty of Arts and Science Manase, Dorin; University Health Network, Data Aggregation, Translation and Architecture Parekh, Rulan; The Hospital for Sick Children, Child Health Evaluative Sciences; The Hospital for Sick Children, Transplant and Regenerative Medicine Centre Silva, Amanda; University Health Network, Data Aggregation, Translation and Architecture Stinson, Jennifer; The Hospital for Sick Children, Child Health Evaluative Sciences; University of Toronto, Lawrence S. Bloomberg Faculty of Nursing
Primary Subject Heading:	Paediatrics
Secondary Subject Heading:	Mental health, Health services research, Patient-centred medicine, Qualitative research, Research methods
Keywords:	Quality in health care < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Transplant medicine < INTERNAL MEDICINE, MENTAL HEALTH, PAEDIATRICS, Paediatric transplant surgery < PAEDIATRIC SURGERY, QUALITATIVE RESEARCH

SCHOLARONE™ Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BMJ

I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1

Title

The creation of an electronic patient-reported outcome measure platform Voxe: A mixed methods study protocol in pediatric solid organ transplantation

Authors

Samantha J. Anthony[1-4], Sarah J. Pol[1], Jia Lin[1], Melanie Barwick[1,5,6], Michael Brudno[7,8], Dorin Manase[7], Rulan S. Parekh[1,2,9,10], Amanda Silva[7], Jennifer Stinson[1,11]

1. Child Health Evaluative Sciences, Peter Gilgan Centre for Research and Learning, The Hospital for Sick Children, Toronto, ON, Canada
2. Transplant and Regenerative Medicine Centre, The Hospital for Sick Children, Toronto, ON, Canada
3. Factor-Inwentash Faculty of Social Work, University of Toronto, Toronto, ON, Canada
4. Canadian Donation and Transplantation Research Program, Edmonton, AB, Canada
5. Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada
6. Temerty Faculty of Medicine, Department of Psychiatry, University of Toronto, Toronto, ON, Canada
7. Data Aggregation, Translation and Architecture, University Health Network, Toronto, ON, Canada
8. Faculty of Arts and Science, Department of Computer Science, University of Toronto, Toronto, ON, Canada
9. Division of Nephrology, The Hospital for Sick Children, Toronto, ON, Canada
10. Division of Nephrology, University Health Network, Toronto, ON, Canada
11. Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, ON, Canada

Author	ORCID
Samantha J. Anthony	0000-0002-1800-2333
Sarah J. Pol	0000-0003-1883-1753
Jia Lin	0000-0002-8691-3358
Melanie Barwick	0000-0002-2478-604X
Michael Brudno	0000-0001-7947-2243
Rulan S. Parekh	0000-0001-6313-5752
Jennifer Stinson	0000-0002-9969-8052

Corresponding author

Samantha J. Anthony

The Hospital for Sick Children

686 Bay Street, Toronto, Ontario, M5G 0A4

E-mail: samantha.anthony@sickkids.ca

Word count: 3506

2

Abstract
Introduction:

Patient-reported outcome measures (PROMs) provide an opportunity for meaningful patient engagement and shared decision-making. The objective of this research program is to improve health outcomes for pediatric solid organ transplant patients by implementing PROMs into clinical care. The current study aims to create Voxe, a pediatric user-centred electronic PROM platform, by engaging patients and healthcare providers throughout the design and development process.

Methods and analysis:

The creation of Voxe will occur over two phases that build on previous research. The user interface design phase employs a 'user-centric' approach to identify end-users' needs and iteratively refine the look and layout of Voxe to meet these needs. Transplant recipients, aged 10 to 17, and healthcare providers will participate in three rounds of testing (24 participants total). Participants will: (1) complete task-based activities (outcomes – effectiveness and efficiency), (2) complete questionnaires (outcome – satisfaction), and (3) participate in a semi-structured interview. The following phase involves software development and Voxe usability testing. Transplant recipients, aged eight to 17, and healthcare providers will participate in four rounds of iterative testing (24 to 40 participants total). The think-aloud technique will be employed, and participants will describe their thoughts and feelings while interacting with a Voxe prototype. Participants will: (1) log into Voxe and complete tasks (outcomes – time on task, successful task completion, frequency of critical and non-critical errors and error-free rate), (2) complete questionnaires (outcome – satisfaction), and (3) participate in a semi-

structured interview. Findings will result in the creation and launch of a user-centred electronic

PROM platform.

Ethics and dissemination:

Research ethics board approval has been provided by The Hospital for Sick Children. This

research is critical to answering methodological and operational questions to inform Voxe

implementation in pediatric clinical settings and facilitate PROM data collection. Future

investigations will include an implementation-effectiveness evaluation.

Article Summary – Strengths and limitations of this study

- By engaging pediatric patients and healthcare providers throughout the design and

  development process, this study will facilitate the creation and launch of an evidence-

  based pediatric user-centred electronic PROM platform prototype called Voxe

- A 'user-centric' approach will consider the needs of pediatric patients and healthcare

  providers at each design phase and allow for iterative modification of wireframes to

  best meet their identified needs.

- The think-aloud technique will facilitate understanding of the end-user's experience

  with Voxe by enabling participants to verbalize their thoughts and feelings while

  interacting with Voxe to complete specific tasks.

- As the ability to speak and read English is a requirement for study participation, the

  perspectives of those who are not able to speak and read English will be missed in these

  phases of the study.

4

- This study builds the foundation for future phases of research which will include

  healthcare provider Voxe orientation and competency training and an implementation-

  effectiveness evaluation.

Keywords

- Quality in health care

- Transplant medicine

- Mental health

- Paediatrics

- Paediatric transplant surgery

- Qualitative research

5

BACKGROUND

For children with end-stage organ failure, transplantation is a life-saving therapy.(1, 2) However, evaluating the success of solid organ transplantation based solely on objective clinical outcomes is insufficient. The patient's subjective assessment is a crucial component in evaluating the burden of disease and can be captured via patient-reported outcome measures (PROMs).(1, 2) PROMs are defined as: "any report of the patient's health condition that comes directly from the patient, without interpretation of the patient's response by a clinician or anyone else" (pg. 2).(3) PROMs can capture a patient's self-assessment of functional status, symptoms, treatment adherence, and multiple domains of well-being and quality of life.(4, 5) In doing so, PROMs give patients a voice in their healthcare and provide an opportunity for meaningful engagement.(6) Research indicates that the systematic collection of PROM data enhances patient-clinician communication and shared decision-making, thereby improving health outcomes.(4, 5, 7, 8) The inclusion of PROMs in clinical care assists in identifying valuable information about the impact of transplantation on patients' symptoms as well as their functional and emotional status. This in turn may help healthcare providers to detect under- and unrecognized problems (e.g., depression, anxiety), resulting in more effective patient care (e.g., initiation of clinical interventions) and an efficient healthcare system.

Innovative opportunities to integrate PROMs into clinical practice have been buoyed by recent advances in eHealth.(9, 10) In particular, the development and implementation of electronic PROMs (ePROMs) can help identify important, patient-valued concerns at the point of care, supporting the delivery of appropriate and timely interventions. Moreover, current platforms that support the use of ePROMs are underdeveloped and require better

6

implementation with clinical care.(2, 6, 7) Further, research on the implementation

effectiveness of ePROMs in pediatric clinical settings is limited,(2, 11) giving rise to concerns

that ePROMs may languish, unused, and fail to realize meaningful outcomes for patients.

Implementation of evidence-based interventions is important to ensure meaningful patient

outcomes.(12) Achieving optimal clinical and health system outcomes for ePROMS will require

more intentional and explicit study of how they might best be implemented prior to

widespread implementation.(1, 2, 5)

The overarching objective of this research program is to improve health outcomes and

transform the delivery of care for pediatric transplant patients in Canada by integrating

ePROMs into standard clinical practice. This program of research uses a phased approach to

target the methodological and practical decisions (e.g., determining which standardized PROMs

to use, identifying goals for collecting PROMs, selecting patients, setting, and timing of

assessment, etc.) needed to guide systematic and effective implementation of ePROMs into

'real-world' pediatric patient care settings.(13) Recently completed foundational research to

explore these questions within pediatric solid organ transplantation consisted of the three

phases of work outlined below.

Phase 1: Systematic review

A systematic review was conducted to identify PROMs used in pediatric solid organ

transplantation.(14) A total of 4,305 studies were identified, of which 62 describing 47 PROMs

were selected for analysis and were appraised for adherence to internationally recommended

guidelines for item generation, item reduction, and psychometric properties.(15) Findings

revealed six standardized PROMs that had undergone psychometric evaluation in a pediatric

solid organ transplant population. This phase of work identified standardized PROMs to consider for implementation into clinical care.

Phase 2: Interviews with key stakeholders

Interviews with key stakeholders across Canada, including: (a) pediatric solid organ transplant recipients, (b) parent(s)/caregiver(s), and (c) healthcare providers, were conducted to explore perspectives regarding ePROMs implementation into clinical practice.(16) Sixty-three participants across five Canadian pediatric transplant centres were interviewed, among whom nearly all (60/63; 95%) were supportive of implementing an ePROM system into clinical practice with the primary goals of: (1) integrating the transplant patient's overall well-being into the clinical care conversation, (2) capturing the patient's voice and increasing patient engagement, and (3) informing pediatric transplant clinical care. Insights for effective PROM implementation included the remote completion of ePROMs in advance of clinical appointments for patients eight to 10 years of age or older.

Phase 3: Consensus workshop

A two-day consensus workshop was hosted in December 2018 in Toronto to further explore how ePROMs could best be implemented into pediatric transplant clinical practice. Workshop proceedings were informed by the results of Phases 1 and 2. The workshop was attended by 25 leading experts in the fields of pediatric solid organ transplantation, PROMs, implementation science, and computational medicine, as well as patients, caregivers, healthcare providers, researchers, and administrators from across Canada. Workshop outcomes included: (1) consensus on key methodological and operational decisions for implementing ePROMs into practice (e.g. which standardized PROMS to utilize, the setting and timing of

8

assessment, as well as the mode for administering ePROMs), (2) a research plan to design,

develop and evaluate the usability and implementation of an ePROM platform, and (3) a

knowledge translation strategy to disseminate research findings to key knowledge users (e.g.

newsletter, peer-reviewed publications, website posting, national and international

presentations). The consensus workshop captured attendees' perspectives on practice and

systems-based facilitators and barriers to implementing ePROMs and was instrumental in

ensuring that future research would be relevant and meaningful to stakeholders.

Study objectives

Results from Phases 1 to 3 inform the current study, Phases 4 and 5.(17) The

overarching aim of the proposed study, which will be conducted within the Transplant and

Regenerative Medicine Centre at The Hospital for Sick Children (SickKids), is to create an

ePROM platform called Voxe, that will capture and implement patient-reported outcomes into

the clinical care workflow for pediatric organ transplant patients. Specifically, Phase 4 aims to

design the user interfaces of the Voxe platform, and Phase 5 aims to develop the Voxe software

and conduct usability testing of Voxe in preparation for a future implementation-effectiveness

trial (Phase 6). A graphical representation of the different research phases is displayed in Figure

1: *Measuring What Matters: Implementing Patient-Reported Outcome Measures into Clinical*

Practice – A Research Program.

9

METHODS

Phase 4: User interface design of Voxe ePROM platform

eHealth technologies designed and developed based on assumptions of end-user motivations, goals or needs, are often less effective than those that engage end-users throughout the process.(10, 18) Thus, a 'user-centric' approach in which end-users (i.e., patients and healthcare providers) are central to the design process will guide the design and development of Voxe. This evidence-based approach will consider the needs of Voxe users at each design phase and will allow for iterative modification of wireframes, which are the static, two-dimensional visual representation or layout of Voxe, to best meet their identified needs.(19-21) A 'user-centric' approach is paramount for user engagement with the platform, ultimately contributing to the effectiveness of the platform itself.(10)

Study participants and inclusion criteria

Purposive sampling will be used to recruit 12 patient participants across age, organ type, sex, gender, and ethnicity from the Transplant and Regenerative Medicine Centre at SickKids to obtain maximum variation.(22) Twelve members of the patients' interdisciplinary healthcare teams at SickKids will also be recruited purposively across professional disciplines, years of practice, sex, gender and ethnicity. This sample size is consistent with testing methods for clinical information systems.(23)

Patients eligible to participate include those who are: (a) 10 to 17 years of age, (b) able to speak and read English, and (c) heart, kidney, liver or lung transplant recipients who are a minimum of three months post-transplant. Patients with significant cognitive impairments, as determined by a healthcare team member, will not be invited to participate. Eligible healthcare

providers include any member of the interdisciplinary healthcare team within the Transplant and Regenerative Medicine Centre at SickKids.

Procedures and outcomes

The design of preliminary Voxe wireframes will be guided by: (1) stakeholder input gleaned from previous phases of research,(14, 16) and (2) design workshop processes, including identification of Voxe users (i.e., patients and healthcare providers) and the tasks they will complete on their respective platforms (i.e., persona and task inventory development). Following the design of preliminary wireframes, a rapid and iterative testing methodology will be used to evaluate, learn and improve Voxe prior to development (i.e., coding and launch).(19) Three rounds of testing sessions will be scheduled with patient and healthcare provider participants to elicit feedback on Voxe design features. Written consent and assent, as well as demographic information, will be obtained prior to study participation.

Each testing session will be conducted virtually via the Personal Health Information Protection Act-compliant version of Zoom or Microsoft Teams. During each session, International Organization for Standardization key performance indicators, consensus-base standards for technology, will be benchmarked and tracked to validate each iteration for success.(24, 25) In particular, objective and subjective standards common in user experience design testing,(26) will be collected to measure: (1) effectiveness – accuracy and completeness with which users achieve specific goals, displayed as a percentage of tasks successfully completed (average task completion rate is 78%; above average is considered successful task completion(27, 28)), and (2) efficiency – resources used in relation to results achieved, represented by the time it takes users to successfully complete the task.(29) Prior to the

1

scheduled testing session, the URL for the testing website will be emailed to the participant.

During the session, participants will complete task-based activities using incremental segments

(i.e., wireframes) of the Voxe platform.

Following the task-based activities, healthcare provider participants will complete the

System Usability Scale, a 10 item Likert scale questionnaire to assess the key performance

indicator satisfaction.(30, 31) The System Usability Scale is considered a reliable way to

evaluate electronic platforms and a score of 68 is considered above average.(30, 31) Patient

participant's overall impression and experience with the Voxe platform will be evaluated using

the Microsoft Desirability Toolkit.(32) Patient participants will select five words from a list of

product reaction words to describe their attitude towards the Voxe platform. Product reaction

words, such as "fun" and "calm" describe intangible emotional response towards the

interface.(33)

Lastly, participants will share their likes and dislikes of the Voxe platform design and

comment on the platform's ease of use and elements of functionality during a virtual semi-

structured qualitative interview. Semi-structured interviews foster reciprocity between the

participant and interviewer, allow the interviewer to ask pertinent follow-up questions to elicit

rich data and enable the participant to express themselves using their own words.(34-36) The

interview guide will be developed by the study team and will be informed by clinical knowledge

and experience. Interviews will be conducted by study team members trained in qualitative

methods. Sessions will be audio-recorded, transcribed verbatim and de-identified to protect

participant confidentiality. Recruitment for Phase 4 began in May 2020.

<u>Data analysis</u>

1

Data collected during the testing sessions, including objective and subjective International Organization for Standardization key performance indicators, will be used to refine Voxe. The research team will utilize content and thematic analysis to categorize the data collected during qualitative interviews.(37-39) Two members of the study team experienced in qualitative methods, will code the data independently, and categories will be reviewed and refined until consensus is reached for emerging themes. Trustworthiness will be achieved by facilitating member checking and soliciting rich description during interviews, as well as hosting frequent team meetings to support in-depth, iterative analysis with reflexive discussion among team members. Analysis will be complete once the research team agrees that thematic saturation is attained.(39) NVivo 12 will be used to manage qualitative data.(40) Quantitative data collected during the testing sessions will be triangulated with qualitative themes to provide a richer understanding of end-users' experience with Voxe. Refinements will be made to the Voxe platform design based on the triangulated data. Three rounds of iterative feedback testing will be conducted with each participant population (i.e. four participants per round) until Voxe is considered acceptable to participating end-users with no further refinements identified.(41, 42) Following the third round of patient and healthcare provider iterative testing, the design team will share the final Voxe patient and healthcare provider annotated wireframes with the development team.

Phase 5: Development of ePROM platform Voxe and usability testing

Usability is defined as the "extent to which a system, product or service can be used by specified users to achieve specified goals with effectiveness, efficiency and satisfaction in a specified context of use".(24) To test Voxe usability, the think-aloud technique will be

1

employed in which participants will verbalize their thoughts and feelings while interacting with

Voxe to complete structured tasks.(43, 44) The think-aloud technique is integral to

understanding the end-user experience with Voxe and will highlight potential barriers to Voxe

adoption that can inform its subsequent implementation.(43, 44) Semi-structured interviews

and data analytics, described below, will also be conducted.(45)

<u>Study participants and inclusion criteria</u>

Purposive sampling will be used to recruit 12 to 20 patient participants across age,

organ type, sex, gender, and ethnicity from the Transplant and Regenerative Medicine Centre

at SickKids. Twelve to 20 members of the patients' interdisciplinary healthcare team will also be

recruited purposively across professional disciplines, years of practice, sex, gender and

ethnicity.(23)

Patients eligible to participate will include those who are: (a) eight to 17 years of age

with capacity to assent/consent, (b) those able to speak and read English, (c) heart, kidney, liver

or lung transplant recipients, and (d) who are a minimum of three months post-transplant.

Informed consent will be obtained from the parents/legal guardians of participants who

provide assent. Eligible healthcare providers include any member of the interdisciplinary

healthcare team within the Transplant and Regenerative Medicine Centre at SickKids who have

worked within their position for a minimum of six months.

<u>Procedures and outcomes</u>

Following Phase 4, the development team will use the Voxe patient and healthcare

provider annotated wireframes to develop the respective interfaces of the Voxe ePROM

platform, using an agile, scrum framework.(19) A scrum framework is a project management

process within a hybrid software development model that applies a flexible development process and places the needs of system end-users at the forefront to ensure that Voxe is both useful and usable.(46, 47) The principles of iterative feedback, incremental development and continual stakeholder involvement are central to this dynamic approach.(46, 47) Feature development will be phased and will include authentication, user dashboards, account settings, privacy/security controls and survey submission/review functionality.

Four rounds of iterative testing will be completed with three to five patients and three to five healthcare providers per round, as is consistent with usability testing methods for clinical information systems.(23) The first two rounds will be conducted in-person or virtual with a member of the study team, using smartphones, tablets and/or computers. Both patient and healthcare provider participants will be asked to complete a core set of tasks on Voxe which will be presented to them in the form of scenarios that they may encounter while interacting with Voxe. For example, patients will be provided with an anonymous username and password, invited to successfully log into Voxe, and navigate Voxe to complete available ePROMs (i.e. PedsQL™ Generic Core Scales(48)). Healthcare providers will be invited to navigate Voxe to view and interpret sample ePROM results. Employing think-aloud methodology, participants will be encouraged to voice out loud what they are looking at, thinking, doing and feeling as they navigate the platform.(43, 45)

The last two testing rounds will be conducted to simulate 'real-world' settings. An automated text message or email with an embedded hyperlink will be sent to patients asking them to access Voxe remotely on a smartphone, tablet or computer. Patients will independently log into Voxe using an anonymous username and password and navigate the

1

platform to complete available ePROMs. Healthcare providers will be asked to access Voxe on a computer and independently navigate the Voxe platform to view and interpret ePROM data entered by patients.

Objective measures to be collected include: (1) time on task – the time it takes to complete each task, (2) successful task completion (fidelity) – when the end-user achieves the end goal of the task successfully (above the average task completion rate of 78% is considered successful(27, 28)), (3) frequency of critical errors – a high severity error that could prevent an end-user from being able to complete a task, (4) frequency of non-critical errors – a low severity error that could decrease the efficiency with which an end-user completes a task, and (5) error-free rate – the percentage of task completions that occurred without any errors.(49, 50) After the completion of task based activities, participant satisfaction will be evaluated. Healthcare provider participants will complete the System Usability Scale. A score on the System Usability Scale that is greater than 68 is considered above average.(30, 31) Patient participants will complete the Microsoft Desirability Toolkit by selecting words from a list of product reaction words to describe their attitude towards the Voxe platform.(32, 33) Following each testing round, in-person or virtual semi-structured interviews will be conducted to ascertain what participants liked or disliked and why, ease of use, elements of functionality in the context of typical practice workflow, as well as suggestions for improvements. Iterative usability testing will also be conducted until Voxe is considered acceptable to participating end-users with no further refinements identified.(41, 42) Interviews will be audio-recorded, transcribed verbatim and de-identified.

Data analysis

Quantitative data including time on task, successful task completion, frequency of critical and non-critical errors, and error-free rate will be analyzed and descriptive statistics will be produced. Similar to Phase 4, qualitative interviews will be subject to content and thematic analysis to identify emerging themes.(37, 38) Themes will be coded and categorized using NVivo 12 according to type and frequency of occurrence.(40) Quantitative and qualitative data will be triangulated to inform changes made to the Voxe platform.

Patient and public involvement

Phases 4 and 5 are informed by the invaluable feedback provided by stakeholders, including pediatric patients, their caregivers and healthcare providers, from previous phases of research.(16) Patients' and healthcare providers' thoughts, feelings and perspectives about Voxe captured through research processes described in this protocol will continue to guide this research program. Stakeholder involvement will ensure the implementation of evidence-based interventions integral to achieving meaningful patient outcomes.

ETHICS AND DISSEMINATION

Ethics approval and consent to participate

Institutional research ethics board approval has been provided by SickKids (REB number: 1000057043 (Phase 4); REB number: 1000067700 (Phase 5)). All participants will provide informed consent or assent prior to their involvement in the study. For participants who provide informed assent, informed consent will be obtained from the parents/legal guardians prior to study participation.

Information security

All interviews will be audio recorded and transcribed verbatim. Transcription will be completed

by a member of the study team. All transcriptions will be de-identified to protect participant

confidentiality. All identifying information, both paper copy and electronic information, will be

kept confidential. Use of data over the course of the study and dissemination of results will

follow standard practice guidelines as determined by the SickKids Research Institute.

Discussion and dissemination

The collection of PROMs provides the opportunity to incorporate patient-centred

perspectives into pediatric clinical practice.(2, 6, 11, 51-54) The creation of the Voxe ePROM

platform will reform the practice of pediatric medicine by enhancing the capacity of patient-

provider partnerships to identify and address issues that are most meaningful to patients.(55)

The design and development of Voxe outlined in this protocol are critical to answering

important methodological and operational questions that will inform the implementation of

ePROMs in pediatric clinical settings.

Engaging patients and healthcare providers throughout Voxe design and development

will result in the creation and launch of a user-centred ePROM platform. For patients, Voxe will

facilitate ePROM data collection in a child friendly and patient-centred manner. For healthcare

providers, Voxe will facilitate convenient and timely review of patient ePROM data,

collaboration within healthcare teams, and shared decision-making discussions between

healthcare providers and patients during clinical encounters.

During Phase 4, patients and healthcare providers will share their likes and dislikes of

the design and comment on Voxe functionality and ease of use. It is critical that Voxe design

iterations integrate this feedback, as the interface needs to be designed in a way that is logical,

intuitive, and user friendly for end-users. This process will ensure that there is an evidence-based iterative design in place before usability testing. In Phase 5, patients and healthcare providers will comment on what they liked or disliked about Voxe and why, Voxe ease of use, and elements of functionality in the context of typical practice workflow, as well as suggestions to improve Voxe. Voxe will be further refined according to this feedback until a final version is produced. The final product will enhance the experience of end-users with systematically tested functionality and design. Following the procedures outlined above, creating an evidence-based ePROM platform will enable these outcomes. Findings from this study will be widely disseminated through infographics, posts on the research team's website, peer-reviewed journal publications and presentations at patient and family educational events as well as scientific and academic conferences. Data collection is expected to be completed by the end of 2021 with publication of results in early 2022.

This research lays the groundwork for future investigations that will include Voxe healthcare provider orientation and competency training as part of a more comprehensive implementation plan. Additionally, an implementation-effectiveness evaluation (Phase 6) of the Voxe ePROM platform will be conducted to explore how Voxe can be effectively implemented in a manner that impacts pediatric transplantation patient's health outcomes and clinical care.

List of abbreviations
ePROM – Electronic patient-reported outcome measure
PROM – Patient-reported outcome measure

Figure Caption
Figure 1: Measuring What Matters: Implementing Patient-Reported Outcome Measures into Clinical Practice – A Research Program

Acknowledgements
The authors thank our patient partners and past and future research participants.

Authors' contributions

All authors (SJA, SJP, JL, MBa, MBr, DM, RSP, AS, JS) contributed to project conception and study design. SJA, SJP and JL drafted the manuscript. All authors (SJA, SJP, JL, MBa, MBr, DM, RSP, AS, JS) read the manuscript and gave final approval of the version to be published.

References

1.   Rossano JW, Cherikh WS, Chambers DC, Goldfarb S, Hayes D, Khush KK, et al. The international thoracic organ transplant registry of the International Society for Heart and Lung Transplantation: Twenty-first pediatric heart transplantation report—2018; Focus theme: Multiorgan transplantation. J Heart Lung Transplant. 2018;37(10):1184-95.

2.   Bevans KB, Moon J, Carle AC, Mara CA, Lai J-S, DiMarco L, et al. Patient reported outcomes as indicators of pediatric health care quality. Acad Pediatr. 2014;14(5):S90-S6.

3.   US Department of Health Human Services Food and Drug Administration. Guidance for industry - Patient-reported outcome measures: Use in medical product development to support labeling claims. Fed Reg. 2009;74(235):65132–3.

4.   Santana M-J, Feeny D. Framework to assess the effects of using patient-reported outcome measures in chronic care management. Qual Life Res. 2014;23(5):1505-13.

5.   Fung CH, Hays RD. Prospects and challenges in using patient-reported outcomes in clinical practice. Qual Life Res. 2008;17(10):1297-302.

6.   Bitton A, Onega T, Tosteson AN, Haas JS. Toward a better understanding of patient-reported outcomes in clinical practice. Am J Manag Care. 2014;20(4):281.

7.   Nelson EC, Eftimovska E, Lind C, Hager A, Wasson JH, Lindblad S. Patient reported outcome measures in practice. BMJ. 2015;350.

8.   Valderas J, Kotzeva A, Espallargues M, Guyatt G, Ferrans C, Halyard M, et al. The impact of measuring patient-reported outcomes in clinical practice: A systematic review of the literature. Qual Life Res. 2008;17(2):179-93.

9.   Forrest CB. Digitization of patient-reported outcomes. Value Health. 2013;16(4):459-60.

10.   McCurdie T, Taneva S, Casselman M, Yeung M, McDaniel C, Ho W, et al. mHealth consumer apps: The case for user-centered design. Biomed Instrum Technol. 2012;46(Suppl 2):49-56.

11.   Huang I-C, Revicki DA, Schwartz CE. Measuring pediatric patient-reported outcomes: Good progress but a long way to go. Springer; 2014.

12.   Hoffmann T, Bennett S, Del Mar C. Evidence-based practice across the health professions-e-book: Elsevier Health Sciences; 2013.

13.   Aaronson N, Elliott T, Greenhalgh J, Halyard M, Hess R, Miller D, et al. User's guide to implementing patient-reported outcomes assessment in clinical practice version 2. 2015.

14.   Anthony SJ, Stinson H, Lazor T, Young K, Hundert A, Santana MJ, et al. Patient-reported outcome measures within pediatric solid organ transplantation: A systematic review. Pediatr Transplant. 2019;23(6):e13518.

15.   Terwee CB, Mokkink LB, Knol DL, Ostelo RW, Bouter LM, de Vet HC. Rating the methodological quality in systematic reviews of studies on measurement properties: A scoring system for the COSMIN checklist. Qual Life Res. 2012;21(4):651-7.

16.   Anthony SJ, Young K, Pol SJ, Selkirk EK, Blydt-Hansen T, Boucher S, et al. Patient-reported outcome measures in pediatric solid organ transplantation: Exploring stakeholder perspectives on clinical implementation through qualitative description. Qual Life Res. 2021.

17.   Meyers DC, Durlak JA, Wandersman A. The quality implementation framework: A synthesis of critical steps in the implementation process. Am J Community Psychol. 2012;50(3-4):462-80.

18.   Verhoeven F, Tanja-Dijkstra K, Nijland N, Eysenbach G, van Gemert-Pijnen L. Asynchronous and synchronous teleconsultation for diabetes care: A systematic literature review. J Diabetes Sci Technol. 2010;4(3):666-84.

19.   Barnum CM. Chapter 1: Establishing the essentials. In: Merken S, editor. Usability testing essentials: ready, set test! 2 ed. Amsterdam: Elsevier; 2020. p. 9-33.

20.   US General Services Administration Technology Transformation Services. Wireframing 2021 [Available from: https://www.usability.gov/how-to-and-tools/methods/wireframing.html.

21.   ProductPlan. Wireframe 2021 [Available from: https://www.productplan.com/glossary/wireframe/.

22.   Palinkas LA, Horwitz SM, Green CA, Wisdom JP, Duan N, Hoagwood K. Purposeful sampling for qualitative data collection and analysis in mixed method implementation research. Adm Policy Ment Health. 2015;42(5):533-44.

23.   Kushniruk AW, Patel VL. Cognitive and usability engineering methods for the evaluation of clinical information systems. J Biomed Inform. 2004;37(1):56-76.

24.   International Organization for Standardization. ISO 9241-11:2018(en) Ergonomics of human-system interaction — Part 11: Usability: Definitions and concepts 2018 [Available from: https://www.iso.org/obp/ui/#iso:std:iso:9241:-11:ed-2:v1:en.

25.   International Organization for Standardization. About us: What we do [Available from: https://www.iso.org/what-we-do.html.

26.   Barnum CM. Chapter 8: Analyzing the findings. In: Merken S, editor. Usability testing essentials: ready, set test! 2 ed. Amsterdam: Elsevier; 2020. p. 287-319.

27.   Sauro J. What Is A Good Task-Completion Rate? Secondary What Is A Good Task-Completion Rate? 2011 [Available from: https://measuringu.com/task-completion/.

28.   Cho H, Powell D, Pichon A, Kuhns LM, Garofalo R, Schnall R. Eye-tracking retrospective think-aloud as a novel approach for a usability evaluation. International journal of medical informatics. 2019;129:366-73.

29.   International Organization for Standardization. ISO 9000:2015(en) Quality management systems — Fundamentals and vocabulary 2015 [Available from: https://www.iso.org/obp/ui/#iso:std:iso:9000:ed-4:v1:en.

30.   Haggerty T, Brabson L, Grogg KA, Herschell AD, Giacobbi Jr P, Sedney C, et al. Usability testing of an electronic health application for patient activation on weight management. Mhealth. 2021;7.

31.   Brooke J. SUS-A quick and dirty usability scale. Usability evaluation in industry. 1996;189(194):4-7.

32.   Barnum C. Chapter 6: Preparing for usability testing. In: Merken S, editor. Usability testing essentials: ready, set test! 2 ed. Amsterdam: Elsevier; 2020. p. 197-248.

33.   Benedek J, Miner T. Measuring desirability: New methods for evaluating desirability in a usability lab setting. Usability Professionals Association. 2002;2003(8-12):57.

34.   Galletta A. Mastering the semi-structured interview and beyond: From research design to analysis and publication: NYU Press; 2013.

35.   Rubin HJ, Rubin IS. Qualitative interviewing: The art of hearing the data. 2 ed. Thousand Oaks, CA: SAGE; 2005.

2

36.   Kallio H, Pietilä AM, Johnson M, Kangasniemi M. Systematic methodological review: Developing a framework for a qualitative semi-structured interview guide. J Adv Nurs. 2016;72(12):2954-65.

37.   Gibbs G. Analysing qualitative data. London, England: SAGE; 2007.

38.   Fereday J, Muir-Cochrane E. Demonstrating rigor using thematic analysis: A hybrid approach of inductive and deductive coding and theme development. Int J Qual Methods. 2006;5(1):80-92.

39.   Elo S, Kyngäs H. The qualitative content analysis process. J Adv Nurs. 2008;62(1):107-15.

40.   Richards L. Using NVivo in qualitative research: Sage; 1999.

41.   Stinson JN, Jibb LA, Nguyen C, Nathan PC, Maloney AM, Dupuis LL, et al. Development and testing of a multidimensional iPhone pain assessment application for adolescents with cancer. J Med Internet Res. 2013;15(3):e51.

42.   Macefield R. How to specify the participant group size for usability studies: A practitioner's guide. J Usability Stud. 2009;5(1):34-45.

43.   Li AC, Kannry JL, Kushniruk A, Chrimes D, McGinn TG, Edonyabo D, et al. Integrating usability testing and think-aloud protocol analysis with "near-live" clinical simulations in evaluating clinical decision support. Int J Med Inform. 2012;81(11):761-72.

44.   Rose AF, Schnipper JL, Park ER, Poon EG, Li Q, Middleton B. Using qualitative studies to improve the usability of an EMR. J Biomed Inform. 2005;38(1):51-60.

45.   Lewis C. Using the "think aloud" method in cognitive interface design. New York: IBM. 1982.

46.   Cervone F. Understanding agile project management methods using scrum. OCLC Systems & Services International digital library perspectives. 2011;1(27):18-22.

47.   Brhel AM, H; Maedche, A; Werder, K. Exploring principles of user-centred agile software development: A literature review. Information and Software Technology. 2015(61):163-81.

48.   Varni J, Seid M, Kurtin P. PedsQL TM 4.0: Reliability and validity of the Pediatric Quality of Life Inventory TM Version 4.0 Generic Core Scales in healthy and patient populations. Med Care. 2001;39:800-12.

49.   US General Services Administration Technology Transformation Services. Planning a Usability Test 2021 [Available from: https://www.usability.gov/how-to-and-tools/methods/planning-usability-testing.html.

50.   Tullis TA, Bill. Chapter 4 – Performance Metrics. Measuring the User Experience. Second ed: Elsevier; 2013. p. 63–97.

51.   Calvert M, Kyte D, Price G, Valderas JM, Hjollund NH. Maximising the impact of patient reported outcome assessment for patients and society. BMJ. 2019;364.

52.   Haverman L, Engelen V, van Rossum MA, Heymans HS, Grootenhuis MA. Monitoring health-related quality of life in paediatric practice: Development of an innovative web-based application. BMC Pediatr. 2011;11(1):1-7.

53.   Haywood K, Brett J, Salek S, Marlett N, Penman C, Shklarov S, et al. Patient and public engagement in health-related quality of life and patient-reported outcomes research: What is important and why should we care? Findings from the first ISOQOL patient engagement symposium. Qual Life Res. 2015;24(5):1069-76.

54.   Cleemput I, Dobbels F. Measuring patient-reported outcomes in solid organ transplant recipients. Pharmacoeconomics. 2007;25(4):269-86.

2

55. Engelen V, Detmar S, Koopman H, Maurice-Stam H, Caron H, Hoogerbrugge P, et al. Reporting health-related quality of life scores to physicians during routine follow-up visits of pediatric oncology patients: Is it effective? Pediatr Blood Cancer. 2012;58(5):766-74.

Figure 1: Measuring What Matters: Implementing Patient-Reported Outcome Measures into Clinical Practice – A Research Program

Phase 1	Phase 2	Phase 3	Phase 4	Phase 5	Phase 6
Systematic Review	**Key Stakeholder Interviews**	**Consensus Workshop**	**Platform Design**	**Usability Testing**	**Implementation Effectiveness Trial**
Completed	Completed	Completed	In Progress		

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

GUIDED – a guideline for reporting for intervention development studies.

Supplementary File 1: Blank Checklist

Item description	Explanation	Page in manuscript where item is located	Other*
1. Report the context for which the intervention was developed.	Understanding the context in which an intervention was developed informs readers about the suitability and transferability of the intervention to the context in which they are considering evaluating, adapting or using the intervention. Context here can include place, organisational and wider socio-political factors that may influence the development and/or delivery of the intervention (15).	9, 10, 13, 14	
2. Report the purpose of the intervention development process.	Clearly describing the purpose of the intervention specifies what it sets out to achieve. The purpose may be informed by research priorities, for example those identified in systematic reviews, evidence gaps set out in practice guidance such as The National Institute for Health and Care Excellence or specific prioritisation exercises such as those undertaken with patients and practitioners through the James Lind Alliance.	8	
3. Report the target population for the intervention development process.	The target population is the population that will potentially benefit from the intervention – this may include patients, clinicians, and/or members of the public. If the target population is clearly described then readers will be able to understand the relevance of the intervention to their own research or practice. Health inequalities, gender and ethnicity are features of the target population that may be relevant to intervention development processes.	9, 10, 13, 14	
4. Report how any published intervention development approach contributed to the development process	Many formal intervention development approaches exist and are used to guide the intervention development process (e.g. 6Squid (16) or The Person Based Approach to Intervention Development (17)). Where a formal intervention development approach is used, it is helpful to describe the process that was followed, including any deviations. More general approaches to intervention development also exist and have been categorised as follows (3):- Target Population-centred intervention development; evidence and theory-based intervention development; partnership intervention development; implementation-based intervention development; efficacy-based intervention development; step or phased-based intervention development; and intervention-specific intervention development (3). These approaches do not always have specific guidance that describe their use. Nevertheless, it is helpful to give a rich description of how any published approach was operationalised	9, 13, 14	
5. Report how evidence from different sources informed the intervention development process.	Intervention development is often based on published evidence and/or primary data that has been collected to inform the intervention development process. It is useful to describe and reference all forms of evidence and data that have informed the development of the intervention because evidence bases can change rapidly, and to explain the manner in which the evidence and/or data was used. Understanding what evidence was and was not available at the time of intervention development can help readers to assess transferability to their current situation.	6-8	
6. Report how/if published theory informed the intervention development process.	Reporting whether and how theory informed the intervention development process aids the reader's understanding of the theoretical rationale that underpins the intervention. Though not mentioned in the e-Delphi or consensus meeting, it became increasingly apparent through the development of our guidance that this theory item could relate to either existing published theory or programme theory	5, 6, 9, 13, 14	
7. Report any use of components from an existing intervention in the current intervention development process.	Some interventions are developed with components that have been adopted from existing interventions. Clearly identifying components that have been adopted or adapted and acknowledging their original source helps the reader to understand and distinguish between the novel and adopted components of the new intervention.	5, 6	
8. Report any guiding principles, people or factors that were prioritised when making decisions during the intervention development process.	Reporting any guiding principles that governed the development of the application helps the reader to understand the authors' reasoning behind the decisions that were made. These could include the examples of particular populations who views are being considered when designing the intervention, the modality that is viewed as being most appropriate, design features considered important for the target population, or the potential for the intervention to be scaled up.	5-8	

1

Item description	Explanation	Page in manuscript where item is located	Other*
9. Report how stakeholders contributed to the intervention development process.	Potential stakeholders can include patient and community representatives, local and national policy makers, health care providers and those paying for or commissioning health care. Each of these groups may influence the intervention development process in different ways. Specifying how differing groups of stakeholders contributed to the intervention development process helps the reader to understand how stakeholders were involved and the degree of influence they had on the overall process. Further detail on how to integrate stakeholder contributions within intervention reporting are available (19).	6-11, 13-15	
10. Report how the intervention changed in content and format from the start of the intervention development process.	Intervention development is frequently an iterative process. The conclusion of the initial phase of intervention development does not necessarily mean that all uncertainties have been addressed. It is helpful to list remaining uncertainties such as the intervention intensity, mode of delivery, materials, procedures, or type of location that the intervention is most suitable for. This can guide other researchers to potential future areas of research and practitioners about uncertainties relevant to their healthcare context.	N/A	
11. Report any changes to interventions required or likely to be required for subgroups.	Specifying any changes that the intervention development team perceive are required for the intervention to be delivered or tailored to specific sub groups enables readers to understand the applicability of the intervention to their target population or context. These changes could include changes to personnel delivering the intervention, to the content of the intervention, or to the mode of delivery of the intervention.	N/A	
12. Report important uncertainties at the end of the intervention development process.	Intervention development is frequently an iterative process. The conclusion of the initial phase of intervention development does not necessarily mean that all uncertainties have been addressed. It is helpful to list remaining uncertainties such as the intervention intensity, mode of delivery, materials, procedures, or type of location that the intervention is most suitable for. This can guide other researchers to potential future areas of research and practitioners about uncertainties relevant to their healthcare context.	N/A	
13. Follow TIDieR guidance when describing the developed intervention.	Interventions have been poorly reported for a number of years. In response to this, internationally recognized guidance has been published to support the high quality reporting of health care? interventions[5] and public health interventions[14]. This guidance should therefore be followed when describing a developed intervention.	N/A	
14. Report the intervention development process in an open access format.	Unless reports of intervention development are available people considering using an intervention cannot understand the process that was undertaken and make a judgement about its appropriateness to their context. It also limits cumulative learning about intervention development methodology and observed consequences at later evaluation, translation and implementation stages. Reporting intervention development in an open access (Gold or Green) publishing format increases the accessibility and visibility of intervention development research and makes it more likely to be read and used. Potential platforms for open access publication of intervention development include open access journal publications, freely accessible funder reports or a study web-page that details the intervention development process.	N/A	

*e.g. if item is reported elsewhere, then the location of this information can be stated here.